

Efficacy and Safety of Low-Dose Colchicine after Myoca

New England Journal of Medicine

381, 2497-2505

DOI: [10.1056/nejmoa1912388](https://doi.org/10.1056/nejmoa1912388)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Inflammation as a Treatment Target after Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 381, 2562-2563.	13.9	34
2	From the editor: Margaritaville blues and Philadelphia news. <i>Journal of Clinical Lipidology</i> , 2019, 13, 857-858.	0.6	0
5	Familial Mediterranean fever is associated with increased risk for ischaemic heart disease and mortality—Perspective derived from a large database. <i>International Journal of Clinical Practice</i> , 2020, 74, e13473.	0.8	14
6	The year in cardiology: cardiovascular prevention. <i>European Heart Journal</i> , 2020, 41, 1157-1163.	1.0	13
7	Anti-inflammatory therapy for secondary prevention after MI. <i>Nature Reviews Cardiology</i> , 2020, 17, 70-71.	6.1	3
8	Mediation of Cardiac Macrophage Activity via Auricular Vagal Nerve Stimulation Ameliorates Cardiac Ischemia/Reperfusion Injury. <i>Frontiers in Neuroscience</i> , 2020, 14, 906.	1.4	6
9	Blood acetylcholinesterase activity is associated with increased 10 year all-cause mortality following coronary angiography. <i>Atherosclerosis</i> , 2020, 313, 144-149.	0.4	5
10	Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Canadian Journal of Cardiology</i> , 2021, 37, 776-785.	0.8	68
11	Secondary prevention after CABG: do new agents change the paradigm?. <i>Current Opinion in Cardiology</i> , 2020, 35, 664-672.	0.8	5
12	Targeting Interleukin-1 and Interleukin-6. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1774-1776.	1.2	12
13	Interleukin-1 ² and Risk of Premature Death in Patients With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1763-1773.	1.2	23
14	Atherosclerosis and inflammation. New therapeutic approaches. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 256-262.	0.1	17
15	Arteriosclerosis e inflamaci ³ n. Nuevos enfoques terap ⁴ uticos. <i>Medicina Clínica</i> , 2020, 155, 256-262.	0.3	33
16	Interleukin-11 is important for vascular smooth muscle phenotypic switching and aortic inflammation, fibrosis and remodeling in mouse models. <i>Scientific Reports</i> , 2020, 10, 17853.	1.6	43
17	Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. <i>Cardiovascular Research</i> , 2020, 116, 2197-2206.	1.8	205
18	Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13424.	1.7	15
19	Cardiology on the cutting edge: updates from the European Society of Cardiology (ESC) Congress 2020. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 448.	0.7	5
20	Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. <i>Life Sciences</i> , 2020, 262, 118510.	2.0	41

#	ARTICLE	IF	CITATIONS
21	Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100629.	0.5	8
22	Cardiovascular and Metabolic Protection by Vitamin E: A Matter of Treatment Strategy?. <i>Antioxidants</i> , 2020, 9, 935.	2.2	31
23	Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. <i>Current Atherosclerosis Reports</i> , 2020, 22, 72.	2.0	14
24	Extracellular vesicle signalling in atherosclerosis. <i>Cellular Signalling</i> , 2020, 75, 109751.	1.7	27
25	Emerging roles of neutrophil-borne S100A8/A9 in cardiovascular inflammation. <i>Pharmacological Research</i> , 2020, 161, 105212.	3.1	30
26	Mechanisms of Stroke in COVID-19. <i>Cerebrovascular Diseases</i> , 2020, 49, 451-458.	0.8	156
27	COVID-19 and the Heart and Vasculature. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2045-2053.	1.1	25
28	Inflammatory Biomarkers for Cardiovascular Risk Stratification in Familial Hypercholesterolemia. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2020, 177, 25-52.	0.9	13
29	Tolerogenic vaccines for the treatment of cardiovascular diseases. <i>EBioMedicine</i> , 2020, 57, 102827.	2.7	5
30	Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1851-1865.	0.9	32
31	Management of multivessel coronary artery disease in patients with non-ST-elevation myocardial infarction: a complex path to precision medicine. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232093852.	1.1	19
32	Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study. <i>Arthritis Research and Therapy</i> , 2020, 22, 169.	1.6	13
33	CircRNA ZNF609 in peripheral blood leukocytes acts as a protective factor and a potential biomarker for coronary artery disease. <i>Annals of Translational Medicine</i> , 2020, 8, 741-741.	0.7	27
34	Viewing atherosclerosis through a crystal lens: How the evolving structure of cholesterol crystals in atherosclerotic plaque alters its stability. <i>Journal of Clinical Lipidology</i> , 2020, 14, 619-630.	0.6	50
35	Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?. <i>Current Atherosclerosis Reports</i> , 2020, 22, 44.	2.0	16
37	A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2020, 2020, 1-9.	0.7	49
38	CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease—The Pros and Cons for Cardioprotection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8533.	1.8	28
39	Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8729.	1.8	16

#	ARTICLE	IF	CITATIONS
40	Direct oral anticoagulants: evidence and unresolved issues. <i>Lancet</i> , The, 2020, 396, 1767-1776.	6.3	100
41	Giving drugs a second chance. <i>Cardiovascular Revascularization Medicine</i> , 2020, 28, 98-99.	0.3	0
42	Recent Development in Therapeutic Cardiac Patches. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 610364.	1.1	47
43	Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2895-2905.	1.2	45
44	Colchicine for Secondary Cardiovascular Prevention in Coronary Disease. <i>Circulation</i> , 2020, 142, 1901-1904.	1.6	19
45	Inflammation and cardiovascular disease: From mechanisms to therapeutics. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100130.	1.3	142
46	The sooner, the better: anti-inflammation in acute myocardial infarction. <i>European Heart Journal</i> , 2020, 41, 4100-4102.	1.0	15
47	<p>Long Sleep Duration is Associated with Increased High-Sensitivity C-Reactive Protein: A Nationwide Study on Chinese Population</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 4423-4434.	1.1	8
48	FDG PET/CT for evaluating systemic arterial inflammation induced by anthracycline-based chemotherapy of Hodgkin lymphoma. <i>Medicine (United States)</i> , 2020, 99, e23259.	0.4	3
49	Vaccination in Atherosclerosis. <i>Cells</i> , 2020, 9, 2560.	1.8	24
50	Exploring Opportunities for Primary Prevention of Unprovoked Venous Thromboembolism: Ready for Prime Time?. <i>Journal of the American Heart Association</i> , 2020, 9, e019395.	1.6	12
51	Gout Is Prevalent but Under-Registered Among Patients With Cardiovascular Events: A Field Study. <i>Frontiers in Medicine</i> , 2020, 7, 560.	1.2	9
52	Carotid artery stenosis and inflammatory biomarkers: the role of inflammation-induced immunological responses affecting the vascular systems. <i>Annals of Translational Medicine</i> , 2020, 8, 1276-1276.	0.7	20
53	Macrophage mitochondrial superoxides as a target for atherosclerotic disease treatment. <i>International Journal of Biochemistry and Cell Biology</i> , 2020, 129, 105883.	1.2	1
54	Multisystem Inflammatory Syndrome With Complete Kawasaki Disease Features Associated With SARS-CoV-2 Infection in a Young Adult. A Case Report. <i>Frontiers in Medicine</i> , 2020, 7, 428.	1.2	32
55	Inflammasomes: a preclinical assessment of targeting in atherosclerosis. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 825-844.	1.5	8
56	Targeting Inflammation After Myocardial Infarction. <i>Current Cardiology Reports</i> , 2020, 22, 110.	1.3	19
57	Cardiovascular magnetic resonance imaging for inflammatory heart diseases. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 598-609.	0.7	10

#	ARTICLE	IF	CITATIONS
58	Cohort profile: BIOVASC-late, a prospective multicentred study of imaging and blood biomarkers of carotid plaque inflammation and risk of late vascular recurrence after non-severe stroke in Ireland. <i>BMJ Open</i> , 2020, 10, e038607.	0.8	4
59	Cardiovascular safety risks associated with gout treatments. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1143-1154.	1.0	2
60	Colchicine Alleviates Cholesterol Crystal-Induced Endothelial Cell Pyroptosis through Activating AMPK/SIRT1 Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-18.	1.9	55
61	Risk for Recurrent Cardiovascular Events and Expected Risk Reduction With Optimal Treatment 1 Year After an Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2020, 133, 7-14.	0.7	7
62	Radionuclide Imaging of the Molecular Mechanisms Linking Heart and Brain in Ischemic Syndromes. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, .	1.3	4
63	What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics. <i>Blood</i> , 2020, 136, 1623-1631.	0.6	23
64	A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: Clinical and therapeutic implications. <i>Atherosclerosis</i> , 2020, 309, 16-26.	0.4	77
65	Colchicine and myocardial infarction: A review. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 652-659.	0.7	21
66	New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention. <i>JAMA Neurology</i> , 2020, 77, 1308.	4.5	20
67	The therapeutic potential of miR-135b in myocardial infarction: Anti-inflammatory trials may be enlightening. <i>International Journal of Cardiology</i> , 2020, 312, 99.	0.8	3
68	Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes. <i>Current Opinion in Cardiology</i> , 2020, 35, 517-523.	0.8	2
69	Acute Myocardial Infarction and Community-acquired <i>Staphylococcus aureus</i> Bloodstream Infection: An Observational Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2647-e2655.	2.9	4
70	Colchicine in COVID-19: an Old Drug, New Use. <i>Current Pharmacology Reports</i> , 2020, 6, 137-145.	1.5	88
73	Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 925-937.	1.5	89
74	Live Imaging of Heart Injury in Larval Zebrafish Reveals a Multi-Stage Model of Neutrophil and Macrophage Migration. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 579943.	1.8	19
75	Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2252-2266.	1.2	52
76	Ideal Dietary Patterns and Foods to Prevent Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2194-2196.	1.2	6
77	Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. <i>American Heart Journal</i> , 2020, 229, 40-51.	1.2	4

#	ARTICLE	IF	CITATIONS
78	Modeling early stage atherosclerosis in a primary human vascular microphysiological system. <i>Nature Communications</i> , 2020, 11, 5426.	5.8	38
79	Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction. <i>Scientific Reports</i> , 2020, 10, 18663.	1.6	10
81	Colchicine for the treatment of coronary artery disease. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 497-504.	2.3	10
82	Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1107-1115.	0.9	12
83	Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <i>European Heart Journal</i> , 2020, 41, 4092-4099.	1.0	174
84	Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease. <i>Circulation</i> , 2020, 142, 1996-1998.	1.6	81
85	Oxidized Lipids and Lipoprotein Dysfunction in Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 139-146.	0.3	6
86	Colchicine for the Treatment of Myocardial Injury in Patients With Coronavirus Disease 2019 (COVID-19) – An Old Drug With New Life?. <i>JAMA Network Open</i> , 2020, 3, e2013556.	2.8	16
87	The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease. <i>Cardiovascular Research</i> , 2021, 117, 1776-1789.	1.8	38
88	Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. <i>PLoS ONE</i> , 2020, 15, e0237665.	1.1	29
89	Targeting Inflammation to Reduce Residual Cardiovascular Risk. <i>Current Atherosclerosis Reports</i> , 2020, 22, 66.	2.0	29
90	Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates. <i>Rheumatology International</i> , 2020, 40, 1741-1751.	1.5	34
91	A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1777-1789.	0.3	51
92	The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia. <i>Current Atherosclerosis Reports</i> , 2020, 22, 67.	2.0	15
93	Residual inflammatory risk: Lessons from trials for the future. <i>Atherosclerosis</i> , 2020, 311, 103-104.	0.4	2
94	Authors' Reply to Vrachatis et al. – Pharmac-Immunomodulatory Therapy in COVID-19. <i>Drugs</i> , 2020, 80, 1501-1503.	4.9	8
95	Inhibition of Interleukin-1 β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1660-1670.	1.2	110
96	Total Burden of Events. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1671-1673.	1.2	1

#	ARTICLE	IF	CITATIONS
97	Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, , .	1.4	10
98	Atherosclerotic Plaque Healing. <i>New England Journal of Medicine</i> , 2020, 383, 846-857.	13.9	201
99	Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1419-1429.	0.3	17
100	Colchicine in Patients With Acute Coronary Syndrome. <i>Circulation</i> , 2020, 142, 1890-1900.	1.6	197
101	Colchicine in Patients with Chronic Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1838-1847.	13.9	1,010
102	Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 2961.	1.0	65
103	Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. <i>Cardiovascular Research</i> , 2021, 117, 2030-2044.	1.8	27
104	The Anti-Inflammatory Effect of Taurine on Cardiovascular Disease. <i>Nutrients</i> , 2020, 12, 2847.	1.7	64
105	Novel Positron Emission Tomography Tracers for Imaging Vascular Inflammation. <i>Current Cardiology Reports</i> , 2020, 22, 119.	1.3	22
106	Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	31
107	What Is the Role of the Inflammation in the Pathogenesis of Heart Failure?. <i>Current Cardiology Reports</i> , 2020, 22, 139.	1.3	36
108	Effect of Low-dose Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients: END-AF Low Dose Trial. <i>Journal of International Medical Research</i> , 2020, 48, 030006052093983.	0.4	17
109	Considering Cause and Effect of Immune Cell Aging on Cardiac Repair after Myocardial Infarction. <i>Cells</i> , 2020, 9, 1894.	1.8	13
110	Regulatory T Cell Stability and Plasticity in Atherosclerosis. <i>Cells</i> , 2020, 9, 2665.	1.8	38
111	Risk Factor Burden and Long-Term Prognosis of Patients With Premature Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e017712.	1.6	50
112	The role of intracoronary imaging in translational research. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1480-1507.	0.7	3
113	¹⁸ F-Sodium Fluoride Positron Emission Tomography Activity Predicts the Development of New Coronary Artery Calcifications. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 534-541.	1.1	14
114	Tackling cardiometabolic risk in the Asia Pacific region. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100096.	1.3	5

#	ARTICLE	IF	CITATIONS
115	Limited impact of impaired awareness of hypoglycaemia and severe hypoglycaemia on the inflammatory profile of people with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2427-2436.	2.2	5
116	Inhibition of macrophage proliferation dominates plaque regression in response to cholesterol lowering. <i>Basic Research in Cardiology</i> , 2020, 115, 78.	2.5	37
117	Prognostic Impact of High-Sensitivity C-Reactive Protein in Patients Undergoing Percutaneous Coronary Intervention According to BMI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2882-2892.	1.1	6
118	Associations Between C-Reactive Protein, Obesity, Sex, and PCI Outcomes. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2893-2895.	1.1	5
120	Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , 2020, 396, 1745-1757.	6.3	192
121	Will Colchicine Soon Be Part of Primary and Secondary Cardiovascular Prevention?. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1697-1699.	0.8	4
122	T Cells in Autoimmunity-Associated Cardiovascular Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 588776.	2.2	24
123	Embracing colchicine as a new cornerstone therapy for coronary disease. <i>Trends in Cardiovascular Medicine</i> , 2020, 31, 505-506.	2.3	1
124	Targeting epigenetics as atherosclerosis treatment: an updated view. <i>Current Opinion in Lipidology</i> , 2020, 31, 324-330.	1.2	14
125	Trained Immunity in Atherosclerotic Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 62-69.	1.1	39
126	Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 347-362.	1.3	23
127	Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 582826.	1.1	3
128	Similar Clinical Course and Significance of Circulating Innate and Adaptive Immune Cell Counts in STEMI and COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3484.	1.0	8
129	A MicroRNA Signature in Acute Coronary Syndrome Patients and Modulation by Colchicine. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 444-455.	1.0	17
130	Noteworthy Literature in Cardiac Anesthesia for 2019. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2020, 24, 138-148.	0.4	2
131	Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials. <i>Advances in Therapy</i> , 2020, 37, 2620-2645.	1.3	5
132	Treating Inflammation Prior to Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009127.	1.4	9
133	The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease. <i>Annals of Pharmacotherapy</i> , 2020, 54, 1021-1029.	0.9	11

#	ARTICLE	IF	CITATIONS
134	Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2602-2618.	1.2	175
135	Is reducing low-density lipoprotein cholesterol all that matters?. <i>Heart</i> , 2020, 106, 1038-1039.	1.2	1
136	Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2020, 382, 1933-1941.	13.9	49
137	Targeted anti-inflammatory therapy is a new insight for reducing cardiovascular events: A review from physiology to the clinic. <i>Life Sciences</i> , 2020, 253, 117720.	2.0	4
138	Neutrophil Phenotypes in Coronary Artery Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 1602.	1.0	14
139	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 88.	1.1	82
140	Repurposing traditional immunomodulators to target the inflammatory burden of atherosclerosis. <i>IJC Heart and Vasculature</i> , 2020, 28, 100535.	0.6	4
141	Apabetalone â€“ÂBET protein inhibition in cardiovascular disease and Type 2 diabetes. <i>Future Cardiology</i> , 2020, 16, 385-395.	0.5	6
142	Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 486-495.	1.8	44
143	Repurposing Available Anti-inflammatory and Immunomodulating Agents for Cardiovascular Risk Management: A Call for Submissions to <i>Current Clinical Pharmacology</i> . <i>Current Clinical Pharmacology</i> , 2020, 15, 2-3.	0.2	1
144	Mon2-monocytes and increased CD-11b expression before transcatheter aortic valve implantation are associated with earlier death. <i>International Journal of Cardiology</i> , 2020, 318, 115-120.	0.8	9
145	Increased the risk of heart failure and comorbidities in patients with gout treatment: a population-based cohort study. <i>Annals of Translational Medicine</i> , 2020, 8, 462-462.	0.7	6
146	Colchicine Use and Incident Coronary Artery Disease inÂMale Patients With Gout. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1722-1728.	0.8	18
147	Metabolic Inflammation and Insulin Resistance in Obesity. <i>Circulation Research</i> , 2020, 126, 1549-1564.	2.0	438
148	Intravenously delivered mesenchymal stem cells prevent microvascular obstruction formation after myocardial ischemia/reperfusion injury. <i>Basic Research in Cardiology</i> , 2020, 115, 40.	2.5	25
149	Colchicineâ€™s effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial. <i>International Journal of Obesity</i> , 2020, 44, 1793-1799.	1.6	38
150	The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.. <i>Clinical Rheumatology</i> , 2020, 39, 2489-2490.	1.0	11
151	Admission Low-Density Lipoprotein Cholesterol Stratified by Circulating CD14++CD16+ Monocytes and Risk for Recurrent Cardiovascular Events Following ST Elevation Myocardial Infarction: Lipid Paradox Revised. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 916-927.	1.1	6

#	ARTICLE	IF	CITATIONS
152	Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy. <i>Circulation Research</i> , 2020, 127, 51-72.	2.0	222
153	High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. <i>Blood Advances</i> , 2020, 4, 2430-2438.	2.5	54
154	Reducing residual cardiovascular risk with novel therapies. <i>Current Opinion in Lipidology</i> , 2020, 31, 108-110.	1.2	7
155	Cardiovascular medications and regulation of COVID-19 receptors expression. <i>International Journal of Cardiology: Hypertension</i> , 2020, 6, 100034.	2.2	8
156	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. <i>In Vivo</i> , 2020, 34, 1567-1588.	0.6	87
157	NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases. <i>Clinical and Translational Medicine</i> , 2020, 10, 91-106.	1.7	113
158	Cerebrovascular Disease and Cognition in Chronic Kidney Disease Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 96.	1.1	39
159	Summarizing 2019 in Cardiovascular Prevention using the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease's ABC Approach. <i>American Journal of Preventive Cardiology</i> , 2020, 2, 100027.	1.3	6
160	Targeting cardiovascular inflammation: next steps in clinical translation. <i>European Heart Journal</i> , 2021, 42, 113-131.	1.0	186
161	Multiparametric Molecular Imaging of Atherosclerosis. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e010494.	1.3	0
162	Modulation of P2Y11-related purinergic signaling in inflammation and cardio-metabolic diseases. <i>European Journal of Pharmacology</i> , 2020, 876, 173060.	1.7	9
163	Acute Coronary Syndromes and the Nontarget Lesion. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1107-1110.	1.2	1
164	Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 22.	1.1	614
165	From CANTOS to CIRT to COLCOT to Clinic. <i>Circulation</i> , 2020, 141, 787-789.	1.6	77
166	Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis. <i>European Journal of Neurology</i> , 2020, 27, 1035-1038.	1.7	34
167	Deciphering post-infarct inflammation: Should it heal, would it hurt?. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 2100-2102.	1.4	1
168	Cardiology and Therapy: A Summary of 2019 and Key Areas of Emerging Research in 2020. <i>Cardiology and Therapy</i> , 2020, 9, 1-4.	1.1	3
169	Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?. <i>Biochemical Pharmacology</i> , 2020, 177, 113894.	2.0	8

#	ARTICLE	IF	CITATIONS
170	Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease. <i>Cardiovascular Diabetology</i> , 2020, 19, 36.	2.7	24
171	Catastrophic stroke burden in a patient with uncontrolled psoriasis and psoriatic arthritis: a case report. <i>BMC Neurology</i> , 2020, 20, 106.	0.8	4
172	Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1135-1147.	1.1	240
173	Something old, something new: a paradigm for considering immune therapies for cardiovascular disease. <i>Cardiovascular Research</i> , 2020, 116, e51-e53.	1.8	2
174	Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. <i>European Heart Journal</i> , 2020, 41, 2952-2961.	1.0	72
175	Mechanisms of cognitive dysfunction in CKD. <i>Nature Reviews Nephrology</i> , 2020, 16, 452-469.	4.1	159
176	Imaging inflammation in atherosclerosis: Exploring all avenues. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2514-2517.	1.4	3
177	Role of Colchicine in Stroke Prevention: An Updated Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104756.	0.7	29
178	Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e014941.	1.6	150
179	Trained Immunity: An Underlying Driver of Inflammatory Atherosclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 284.	2.2	89
180	E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 106.	1.1	5
181	Introducing variability in targeting the microtubules: Review of current mechanisms and future directions in colchicine therapy. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00616.	1.1	37
182	Colchicine for acute and chronic coronary syndromes. <i>Heart</i> , 2020, 106, 1555-1560.	1.2	38
183	The development of a targeted and more potent, anti-inflammatory derivative of colchicine: Implications for gout. <i>Biochemical Pharmacology</i> , 2020, 180, 114125.	2.0	10
184	Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature. <i>Immunological Investigations</i> , 2021, 50, 884-890.	1.0	18
185	Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease. <i>JAMA Cardiology</i> , 2020, 5, 1136.	3.0	59
186	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019. <i>JAMA Network Open</i> , 2020, 3, e2013136.	2.8	344
187	The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232092456.	1.1	8

#	ARTICLE	IF	CITATIONS
188	ATP-sensitive potassium channels gene polymorphism rs1799858 affects the risk of macro-/micro-vascular arteriosclerotic event in patients with increased low-density lipoprotein cholesterol levels. <i>Lipids in Health and Disease</i> , 2020, 19, 147.	1.2	3
189	Platelets as therapeutic targets to prevent atherosclerosis. <i>Atherosclerosis</i> , 2020, 307, 97-108.	0.4	47
192	Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. <i>Arthritis Research and Therapy</i> , 2020, 22, 28.	1.6	104
193	A Novel Molecular Pathway of Plaque Vulnerability Reveals a Cholesterol-Independent Effect of Statins and Supports Inflammation as a Therapeutic Target. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1710-1713.	0.8	1
194	Trends in cardiogenic shock complicating acute myocardial infarction. <i>European Journal of Heart Failure</i> , 2020, 22, 664-672.	2.9	74
195	The cholinergic anti-inflammatory pathway could be an important mechanism underlying the comorbidity of depression and cardiovascular disease: A comment to Shao et al.. <i>Psychiatry Research</i> , 2020, 286, 112881.	1.7	3
196	Peri-coronary inflammation is associated with findings on coronary computed tomography angiography and fractional flow reserve. <i>Journal of Cardiovascular Computed Tomography</i> , 2020, 14, 483-489.	0.7	29
197	Intracranial Atherosclerosis Treatment. <i>Stroke</i> , 2020, 51, e49-e53.	1.0	35
198	Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective. <i>Cardiovascular Intervention and Therapeutics</i> , 2020, 35, 117-129.	1.2	30
199	Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India. <i>Journal of Clinical Lipidology</i> , 2020, 14, e1-e13.	0.6	17
200	60 Years of clonal hematopoiesis research: From X-chromosome inactivation studies to the identification of driver mutations. <i>Experimental Hematology</i> , 2020, 83, 2-11.	0.2	24
201	Reappraising the role of inflammation in heart failure. <i>Nature Reviews Cardiology</i> , 2020, 17, 269-285.	6.1	389
202	Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions. <i>Current Atherosclerosis Reports</i> , 2020, 22, 3.	2.0	6
203	Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 2974-2982.	1.0	185
204	Plasma Metabolic Signature of Atherosclerosis Progression and Colchicine Treatment in Rabbits. <i>Scientific Reports</i> , 2020, 10, 7072.	1.6	7
205	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. <i>CJC Open</i> , 2020, 2, 402-415.	0.7	6
206	Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 78.	1.1	21
207	Endothelial-to-Mesenchymal Transition, Vascular Inflammation, and Atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 53.	1.1	72

#	ARTICLE	IF	CITATIONS
209	Colchicine for Secondary Cardiovascular Prevention: A Systematic Review. <i>Pharmacotherapy</i> , 2020, 40, 575-583.	1.2	3
211	The Greek study in the effects of colchicine in COVID-19 complications prevention (GRECCO-19 study): Rationale and study design. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 42-45.	0.4	114
212	Immunometabolism: a key target to improve microcirculation in ageing. <i>Cardiovascular Research</i> , 2020, 116, e48-e50.	1.8	2
213	COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 620-632.	0.4	351
214	A perspective on targeting inflammation and cytokine actions in atherosclerosis. <i>Future Medicinal Chemistry</i> , 2020, 12, 613-626.	1.1	15
215	Single Cell RNA Sequencing in Atherosclerosis Research. <i>Circulation Research</i> , 2020, 126, 1112-1126.	2.0	84
216	Neutrophil Extracellular Traps Participate in Cardiovascular Diseases. <i>Circulation Research</i> , 2020, 126, 1228-1241.	2.0	198
217	Vaccination Strategies and Immune Modulation of Atherosclerosis. <i>Circulation Research</i> , 2020, 126, 1281-1296.	2.0	49
218	Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 468-472.	1.0	20
219	Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 255-255.	1.4	48
220	Coronary Heart Disease: Have We Reached a Plateau in Primary Prevention?. <i>Journal of the American Heart Association</i> , 2020, 9, e04963.	1.6	10
221	Comprehensive plaque assessment with serial coronary CT angiography: translation to bedside. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 2335-2346.	0.7	10
222	Low-Dose Colchicine after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2020, 382, 1666-1668.	13.9	0
223	Anti-inflammatory Therapy in Rheumatoid Arthritis to Improve Cardiovascular Outcome. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1700-1702.	0.8	2
224	Optimization of stroke prevention: colchicine may be an option. <i>European Journal of Neurology</i> , 2020, 27, 1099-1099.	1.7	1
226	The relation between healthy lifestyle changes and decrease in systemic inflammation in patients with stable cardiovascular disease. <i>Atherosclerosis</i> , 2020, 301, 37-43.	0.4	24
227	Colchicine Toxicity. <i>JACC: Case Reports</i> , 2020, 2, 678-680.	0.3	10
228	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. <i>Journal of Autoimmunity</i> , 2020, 111, 102468.	3.0	103

#	ARTICLE	IF	CITATIONS
229	Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 538-564.	1.8	64
230	Sex as a Biological Variable in Atherosclerosis. <i>Circulation Research</i> , 2020, 126, 1297-1319.	2.0	190
231	Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. <i>Circulation Research</i> , 2020, 126, 1260-1280.	2.0	391
232	IL-6 in pulmonary hypertension: why novel is not always best. <i>European Respiratory Journal</i> , 2020, 55, 2000314.	3.1	21
233	Opposing effects of HNP1 (β -defensin-1) on plasma cholesterol and atherogenesis. <i>PLoS ONE</i> , 2020, 15, e0231582.	1.1	11
234	Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention. <i>Journal of Clinical Medicine</i> , 2020, 9, 1033.	1.0	4
235	The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 13-22.	1.1	34
236	Effects of Colchicine on Atherosclerotic Plaque Stabilization: a Multimodality Imaging Study in an Animal Model. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 150-160.	1.1	19
237	Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication?. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 1-10.	1.0	7
238	Safety and Efficacy of Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 23, 1-6.	0.3	17
239	Nox2+ myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1. <i>Cardiovascular Research</i> , 2021, 117, 162-177.	1.8	28
240	Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. <i>American Heart Journal</i> , 2021, 232, 105-115.	1.2	15
241	GSK669, a NOD2 receptor antagonist, inhibits thrombosis and oxidative stress via targeting platelet GPVI. <i>Biochemical Pharmacology</i> , 2021, 183, 114315.	2.0	13
242	Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality. <i>JAMA Cardiology</i> , 2021, 6, 587.	3.0	35
243	Editorial commentary: Balancing progress and practice: Preventive cardiology in the 2020s. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 57-58.	2.3	0
244	New technologies for intensive prevention programs after myocardial infarction: rationale and design of the NET-IPP trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 153-161.	1.5	8
245	Immunomodulation of the NLRP3 Inflammasome in Atherosclerosis, Coronary Artery Disease, and Acute Myocardial Infarction. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 23-34.	1.1	58
246	Colchicine in Acute Coronary Syndrome: A Systematic Review. <i>Annals of Pharmacotherapy</i> , 2021, 55, 187-197.	0.9	11

#	ARTICLE	IF	CITATIONS
247	Role of Heat Shock Protein 27 in Modulating Atherosclerotic Inflammation. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 3-12.	1.1	16
248	Inflammation and cardiovascular diseases: lessons from seminal clinical trials. <i>Cardiovascular Research</i> , 2021, 117, 411-422.	1.8	59
249	Predicting 10-year risk of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH. <i>International Journal of Cardiology</i> , 2021, 325, 140-148.	0.8	12
250	Sex Differences in the Inflammatory Response: Pharmacological Opportunities for Therapeutics for Coronary Artery Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 333-359.	4.2	15
251	Combating Inflammation in Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2021, 30, 197-206.	0.2	39
252	Immunometabolic control of trained immunity. <i>Molecular Aspects of Medicine</i> , 2021, 77, 100897.	2.7	71
253	The Role of Colchicine in Coronary Artery Disease. <i>Current Problems in Cardiology</i> , 2021, 46, 100690.	1.1	3
255	Coronary heart disease and atrial fibrillation: a vicious cycle. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 320, H1-H12.	1.5	61
256	Greater coronary lipid core plaque assessed by near-infrared spectroscopy intravascular ultrasound in patients with elevated xanthine oxidoreductase: a mechanistic insight. <i>Heart and Vessels</i> , 2021, 36, 597-604.	0.5	7
257	Drug repurposing? Cardiovascular effect of colchicine on patients with coronary artery disease: A systematic review and meta-analysis. <i>Journal of Cardiology</i> , 2021, 77, 576-582.	0.8	11
258	Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition. <i>Annual Review of Medicine</i> , 2021, 72, 447-458.	5.0	12
259	New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. <i>Annual Review of Medicine</i> , 2021, 72, 431-446.	5.0	9
260	Updating concepts on atherosclerotic inflammation: From pathophysiology to treatment. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13467.	1.7	22
261	Prevalence and prognostic impact of hsCRP elevation are age-dependent in women but not in men undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E936-E944.	0.7	3
262	Micro- and macrovascular cardiac allograft vasculopathy in relation to 91 cardiovascular biomarkers in heart transplant recipients—An exploratory study. <i>Clinical Transplantation</i> , 2021, 35, e14133.	0.8	6
263	Recent efforts in drug discovery on vascular inflammation and consequent atherosclerosis. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 411-427.	2.5	7
264	Effect of Yugen tongyu Granules in Patients with Stable Coronary Artery Disease on Reducing Adverse Cardiovascular Events: A Double-Blind Controlled Trial. <i>Journal of Alternative and Complementary Medicine</i> , 2021, 27, 142-149.	2.1	3
265	A tale of two therapies lipid-lowering vs. anti-inflammatory therapy: a false dichotomy?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 238-241.	1.4	12

#	ARTICLE	IF	CITATIONS
266	GlycA for long-term outcome in T2DM secondary prevention. <i>Diabetes Research and Clinical Practice</i> , 2021, 171, 108583.	1.1	6
267	Coronary computed tomography angiography in asymptomatic patients: Still a taboo or precision medicine?. <i>Atherosclerosis</i> , 2021, 317, 47-49.	0.4	6
268	Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underling possible safety concerns. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e18-e19.	1.4	9
269	Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells. <i>Vascular Pharmacology</i> , 2021, 137, 106822.	1.0	10
270	<i>RIPK1</i> Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF- κ B Activation and Atherogenesis in Mice. <i>Circulation</i> , 2021, 143, 163-177.	1.6	102
271	Controversies about the cardiovascular effects of OM3FA. Did inappropriate placebos skew clinical trial results?. <i>Pharmacological Research</i> , 2021, 164, 105368.	3.1	4
273	Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 550-557.	0.5	109
274	Low-dose colchicine prevents sympathetic denervation after myocardial ischemia-reperfusion: a new potential protective mechanism. <i>Future Science OA</i> , 2021, 7, FSO656.	0.9	9
275	Colchicine for secondary prevention in coronary disease. <i>European Heart Journal</i> , 2021, 42, 1060-1061.	1.0	4
276	Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2021, 10, e018993.	1.6	65
277	Ecce urate. <i>Rheumatology</i> , 2021, 60, 8-10.	0.9	0
278	A case of Dressler's syndrome successfully treated with colchicine and acetaminophen. <i>Journal of Cardiology Cases</i> , 2021, 23, 131-135.	0.2	2
279	Metabolic profiling of angiotensin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis. <i>European Heart Journal</i> , 2021, 42, 1160-1169.	1.0	33
280	Pericoronary adipose tissue computed tomography attenuation distinguishes different stages of coronary artery disease: a cross-sectional study. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 298-306.	0.5	52
281	Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2021, 140, 33-38.	0.7	40
282	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 49-56.	2.3	12
283	Colchicine and coronary artery disease: a virtuous adoption. <i>European Heart Journal</i> , 2021, 42, 2796-2797.	1.0	3
284	Research in brief: Colchicine for chronic coronary disease: a recent randomised controlled trial. <i>Clinical Medicine</i> , 2021, 21, e1-e1.	0.8	0

#	ARTICLE	IF	CITATIONS
285	How to manage patients with polyvascular atherosclerotic disease. Position paper of the International Union of Angiology. <i>International Angiology</i> , 2021, 40, 29-41.	0.4	6
286	Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches. <i>Journal of Molecular Medicine</i> , 2021, 99, 335-348.	1.7	83
287	Suspected COVID-19-induced Myopericarditis. <i>Ochsner Journal</i> , 2021, 21, 181-186.	0.5	9
288	Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. <i>PLoS Medicine</i> , 2021, 18, e1003513.	3.9	70
289	An undiagnosed patient with skin rash, polyarthritis, and edema responding to low-dose colchicine: A case report. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110245.	0.2	1
291	The year in cardiovascular medicine 2020: acute coronary syndromes and intensive cardiac care. <i>European Heart Journal</i> , 2021, 42, 884-895.	1.0	7
293	NLRP3 inflammasome as a key driver of vascular disease. <i>Cardiovascular Research</i> , 2022, 118, 372-385.	1.8	84
294	Interleukin-6, C-reactive protein, fibrinogen, and risk of recurrence after ischaemic stroke: Systematic review and meta-analysis. <i>European Stroke Journal</i> , 2021, 6, 62-71.	2.7	35
295	The Impact of Depression and Anxiety on Cardiovascular Disease Risk and Outcomes in Women. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	5
296	Phosphodiesterase-5a Knock-out Suppresses Inflammation by Down-Regulating Adhesion Molecules in Cardiac Rupture Following Myocardial Infarction. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 816-823.	1.1	6
297	Metabolic Consequences of Efferocytosis and Its Impact on Atherosclerosis. <i>Immunometabolism</i> , 2021, 3, .	0.7	15
298	Macrophages Stimulate Epicardial <i>vegfa</i> Expression to Trigger Cardiomyocyte Proliferation in Larval Zebrafish Heart Regeneration. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
299	Neutrophil Gelatinase-Associated Lipocalin (NGAL) Measured at Admission is Associated with Development of Late Cardiogenic Shock and Mortality in Patients with ST-Segment Elevation Myocardial Infarction. <i>Shock</i> , 2021, Publish Ahead of Print, 255-259.	1.0	7
300	Update on the Inflammatory Hypothesis of Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2021, 23, 6.	1.3	14
301	Psoriatic arthritis and the association with cardiometabolic disease: a narrative review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2199827.	1.2	31
303	Colchicine for the prevention of ischemic stroke: An updated meta-analysis of randomized clinical trials. <i>Brain Circulation</i> , 2021, 7, 187.	0.7	2
304	Repurposing colchicine's journey in view of drug-to-drug interactions. A review. <i>Toxicology Reports</i> , 2021, 8, 1389-1393.	1.6	6
305	Colchicine Use in Acute Coronary Syndromes: An Update. <i>Angiology</i> , 2021, 72, 503-510.	0.8	2

#	ARTICLE	IF	CITATIONS
306	Response to: "Correspondence on "Anti-inflammatory therapy for COVID-19 infection: the case for colchicine" by Perricone et al. Annals of the Rheumatic Diseases, 2023, 82, e82-e82.	0.5	1
307	Multitarget Approach to Cardiogenic Shock after Acute Myocardial Infarction: Extracorporeal Life Support (ECLS) and Beyond. Membranes, 2021, 11, 87.	1.4	2
308	Effect of Lipids and Lipoproteins on Hematopoietic Cell Metabolism and Commitment in Atherosclerosis. Immunometabolism, 2021, 3, e210014.	0.7	16
310	Inflammation as a determinant of healing response after coronary stent implantation. International Journal of Cardiovascular Imaging, 2021, 37, 791-801.	0.7	12
311	Efficacy and safety of colchicine for secondary prevention of coronary heart disease: a systematic review and meta-analysis. Internal and Emergency Medicine, 2021, 16, 487-496.	1.0	8
312	Adverse events of colchicine for cardiovascular diseases: a comprehensive meta-analysis of 14,188 patients from 21 randomized controlled trials. Journal of Cardiovascular Medicine, 2021, 22, 637-644.	0.6	30
313	SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress. Frontiers in Physiology, 2020, 11, 605908.	1.3	89
314	Molecular imaging of inflammation crosstalk along the cardio-renal axis following acute myocardial infarction. Theranostics, 2021, 11, 7984-7994.	4.6	22
315	Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes. Frontiers in Cardiovascular Medicine, 2020, 7, 631398.	1.1	14
316	The potential role of Colchicine in preventing coronary vascular disease in childhood-onset lupus: a new view on an old drug. Pediatric Rheumatology, 2021, 19, 15.	0.9	2
317	High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. Current Pharmaceutical Design, 2021, 27, 263-275.	0.9	27
318	Prolonged Increases in Public-Payer Spending and Prices After Unapproved Drug Initiative Approval of Colchicine. JAMA Internal Medicine, 2021, 181, 284.	2.6	7
319	Lactobacillus plantarum 299v probiotic supplementation in men with stable coronary artery disease suppresses systemic inflammation. Scientific Reports, 2021, 11, 3972.	1.6	11
320	USPIOs as Targeted Contrast Agents in Cardiovascular Magnetic Resonance Imaging. Current Cardiovascular Imaging Reports, 2021, 14, 1.	0.4	6
321	NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases. Molecules, 2021, 26, 976.	1.7	33
322	Inflammation-Related Risk Loci in Genome-Wide Association Studies of Coronary Artery Disease. Cells, 2021, 10, 440.	1.8	13
323	Assessing Cardiovascular Risk by Using the Fat Attenuation Index in Coronary CT Angiography. Radiology: Cardiothoracic Imaging, 2021, 3, e200563.	0.9	29
324	Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis. Medicine (United States), 2021, 100, e24579.	0.4	10

#	ARTICLE	IF	CITATIONS
325	Inflammatory process as an etiological and prognostic factor of stroke and the goal of potential treatment strategies. <i>Pharmacotherapy in Psychiatry and Neurology</i> , 2021, 36, 297-311.	0.1	0
326	N-Doped Carbon Dots as a Fluorescent Nanosensor for Determination of Colchicine Based on Inner Filter Effect. <i>Journal of Fluorescence</i> , 2021, 31, 675-684.	1.3	20
327	Novel Applications for Invasive and Non-invasive Tools in the Era of Contemporary Percutaneous Coronary Revascularisation. <i>Current Cardiology Reviews</i> , 2022, 18, .	0.6	3
328	A narrative review of low-dose rivaroxaban in patients with atherothrombotic cardiovascular disease: vascular protection beyond anticoagulation. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 130-141.	0.7	5
329	ApoB-Specific CD4+ T Cells in Mouse and Human Atherosclerosis. <i>Cells</i> , 2021, 10, 446.	1.8	17
330	Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review. <i>Current Respiratory Medicine Reviews</i> , 2021, 16, 165-183.	0.1	0
331	Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 634-640.	1.1	10
332	A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 101-112.	1.6	10
333	Deficiency of Endothelial CD40 Induces a Stable Plaque Phenotype and Limits Inflammatory Cell Recruitment to Atherosclerotic Lesions in Mice. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1530-1540.	1.8	14
334	COVID-19 cardiac injury and the use of colchicine. <i>BMJ Case Reports</i> , 2021, 14, e241047.	0.2	5
336	Colchicine for Left Ventricular Infarct Size Reduction in Acute Myocardial Infarction: A Phase II, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Protocol "The COVERT-MI Study. <i>Cardiology</i> , 2021, 146, 151-160.	0.6	12
337	Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. <i>RMD Open</i> , 2021, 7, e001455.	1.8	183
338	Bazedoxifene exhibits anti-inflammation and anti-atherosclerotic effects via inhibition of IL-6/IL-6R/STAT3 signaling. <i>European Journal of Pharmacology</i> , 2021, 893, 173822.	1.7	22
339	The tandem stenosis mouse model: Towards understanding, imaging, and preventing atherosclerotic plaque instability and rupture. <i>British Journal of Pharmacology</i> , 2022, 179, 979-997.	2.7	14
340	Experimental Agents for the Treatment of Atherosclerosis: New Directions. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 161-179.	1.5	9
341	Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study. <i>Kardiologiya</i> , 2021, 61, 15-27.	0.3	41
342	INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". <i>Obesity and Metabolism</i> , 2021, 18, 5-99.	0.4	49
343	A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV. <i>Aids</i> , 2021, 35, 1041-1050.	1.0	10

#	ARTICLE	IF	CITATIONS
344	Contemporary outcomes studies to identify and mitigate the risk in patients with premature cardiovascular disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 559-570.	0.7	4
345	The multifaceted contribution of platelets in the emergence and aftermath of acute cardiovascular events. <i>Atherosclerosis</i> , 2021, 319, 132-141.	0.4	25
347	Emerging views of statin pleiotropy and cholesterol lowering. <i>Cardiovascular Research</i> , 2022, 118, 413-423.	1.8	54
349	Immuno-metabolic interfaces in cardiac disease and failure. <i>Cardiovascular Research</i> , 2022, 118, 37-52.	1.8	6
350	Colchicine in Patients with Chronic Coronary Disease. <i>New England Journal of Medicine</i> , 2021, 384, 776-779.	13.9	12
351	Hyperuricemia and Cardiovascular Implications. <i>WSEAS Transactions on Biology and Biomedicine</i> , 2021, 17, 143-148.	0.3	2
352	Pathophysiologic mechanisms of cerebral endotheliopathy and stroke due to Sars-CoV-2. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1179-1192.	2.4	16
353	A New Requirement for Publication: Access to Effective Drugs for Ethical Reasons, The Example of Heart Failure. <i>ESC Heart Failure</i> , 2021, 8, 799-801.	1.4	1
354	Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. <i>Nature Reviews Cardiology</i> , 2021, 18, 435-453.	6.1	88
355	Myocardial Infarction Complicated by Ischemic Stroke: Risk Factors, Prognosis, Unresolved Problems and Possible Methods of Prevention. <i>Rational Pharmacotherapy in Cardiology</i> , 2021, 17, 73-82.	0.3	0
356	Association of inflammatory disease and long-term outcomes among young adults with myocardial infarction: the Mass General Brigham YOUNG-MI Registry. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 352-359.	0.8	10
357	Potential therapeutic applications of phytoconstituents as immunomodulators: Pre-clinical and clinical evidences. <i>Phytotherapy Research</i> , 2021, 35, 3702-3731.	2.8	15
358	C-Reactive Protein as a Risk Marker for Post-Infarct Heart Failure over a Multi-Year Period. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3169.	1.8	17
359	Colchicine efficacy and safety for the treatment of cardiovascular diseases. <i>Internal and Emergency Medicine</i> , 2021, 16, 1691-1700.	1.0	13
360	Efficacy and safety of colchicine for the prevention of major cardiovascular and cerebrovascular events in patients with coronary artery disease: a systematic review and meta-analysis on 12,869 patients. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1916-1925.	0.8	25
361	Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting. <i>Acta Diabetologica</i> , 2021, 58, 949-957.	1.2	15
362	Impact of Baseline Neutrophil-to-Lymphocyte Ratio on Long-Term Prognosis in Patients With Atrial Fibrillation. <i>Angiology</i> , 2021, 72, 819-828.	0.8	14
363	Low-dose colchicine in type 2 diabetes with microalbuminuria: A double-blind randomized clinical trial. <i>Journal of Diabetes</i> , 2021, 13, 827-836.	0.8	7

#	ARTICLE	IF	CITATIONS
364	Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events. <i>Atherosclerosis</i> , 2021, 320, 31-37.	0.4	7
365	Risk and clinical outcomes of acute myocardial infarction and acute ischemic stroke following gram-negative bloodstream infection. <i>International Journal of Cardiology: Hypertension</i> , 2021, 8, 100079.	2.2	1
366	Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 721-724.	2.9	10
367	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	1.0	63
369	Managing Cardiovascular Risk in Patients with Rheumatic Disease. <i>Medical Clinics of North America</i> , 2021, 105, 247-262.	1.1	9
370	Polymorphism of Interleukin-1 Gene Cluster in Polish Patients with Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 990.	1.0	3
371	Therapeutic Implications of NLRP3-Mediated Inflammation in Coronary Artery Disease. <i>Cardiology in Review</i> , 2021, Publish Ahead of Print, .	0.6	9
372	Cardiovascular Outcomes With Anti-Inflammatory Therapies: Review of Literature. <i>Current Problems in Cardiology</i> , 2021, 47, 100840.	1.1	1
373	C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 591714.	1.1	47
374	Micro Optical Coherence Tomography for Coronary Imaging. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 613400.	1.1	5
375	Associations of Adiposity, Circulating Protein Biomarkers, and Risk of Major Vascular Diseases. <i>JAMA Cardiology</i> , 2021, 6, 276.	3.0	36
376	Sex- and Gender-Based Pharmacological Response to Drugs. <i>Pharmacological Reviews</i> , 2021, 73, 730-762.	7.1	80
377	Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2212-2220.	2.3	24
378	Resistin is a risk factor for all-cause mortality in elderly Finnish population: A prospective study in the OPERA cohort. <i>PLoS ONE</i> , 2021, 16, e0248015.	1.1	5
379	Evolution and Outcomes of Premature Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2021, 23, 36.	1.3	8
380	Pyroptosis is a critical immune-inflammatory response involved in atherosclerosis. <i>Pharmacological Research</i> , 2021, 165, 105447.	3.1	80
381	Role of Inflammation in Coronary Epicardial and Microvascular Dysfunction. <i>European Cardiology Review</i> , 2021, 16, e13.	0.7	26
382	Colchicine in coronary artery disease. <i>Postgraduate Medical Journal</i> , 2021, , postgradmedj-2020-139611.	0.9	1

#	ARTICLE	IF	CITATIONS
383	Beyond Self-Recycling: Cell-Specific Role of Autophagy in Atherosclerosis. <i>Cells</i> , 2021, 10, 625.	1.8	20
384	Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis. <i>Cells</i> , 2021, 10, 723.	1.8	12
385	Colchicine and SARS-CoV-2: Management of the hyperinflammatory state. <i>Respiratory Medicine</i> , 2021, 178, 106322.	1.3	44
386	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2021, 57, 2100048.	3.1	152
387	Imaging of the Pericoronary Adipose Tissue (PCAT) Using Cardiac Computed Tomography. <i>Journal of Thoracic Imaging</i> , 2021, 36, 149-161.	0.8	24
388	Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal</i> , 2021, 42, 2765-2775.	1.0	119
389	Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine. <i>RMD Open</i> , 2021, 7, e001560.	1.8	2
390	Deoxyribonuclease 1 Q222R single nucleotide polymorphism and long-term mortality after acute myocardial infarction. <i>Basic Research in Cardiology</i> , 2021, 116, 29.	2.5	7
391	Colchicine—“an old dog with new tricks”. <i>Nature Metabolism</i> , 2021, 3, 451-452.	5.1	6
392	Clonal haematopoiesis and cardiovascular diseases: A growing relationship. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 316-324.	0.7	1
393	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003183.	1.6	7
394	Time to commence or time out for colchicine in secondary prevention of cardiovascular disease?. <i>European Heart Journal</i> , 2021, 42, 2776-2779.	1.0	4
395	Is Colchicine Beneficial for the Prevention of Cardiovascular Events After Myocardial Infarction?. <i>Angiology</i> , 2021, 72, 501-502.	0.8	0
396	NLRP3 Inflammasome as a Common Denominator of Atherosclerosis and Abdominal Aortic Aneurysm. <i>Circulation Journal</i> , 2021, 85, 2129-2136.	0.7	11
397	Cells of the Immune System in Cardiac Remodeling: Main Players in Resolution of Inflammation and Repair After Myocardial Infarction. <i>Frontiers in Immunology</i> , 2021, 12, 664457.	2.2	106
400	Editorial commentary: A new era for preventive cardiology. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 195-197.	2.3	0
401	Interleukin-1 blockade with RPH-104 in patients with acute ST-elevation myocardial infarction: study design and rationale. <i>Journal of Translational Medicine</i> , 2021, 19, 169.	1.8	3
402	The changing landscape of atherosclerosis. <i>Nature</i> , 2021, 592, 524-533.	13.7	921

#	ARTICLE	IF	CITATIONS
403	Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1, Interleukin-6 and Beyond. <i>Cells</i> , 2021, 10, 951.	1.8	63
404	Atherothrombosis in Acute Coronary Syndromes—From Mechanistic Insights to Targeted Therapies. <i>Cells</i> , 2021, 10, 865.	1.8	7
405	Anti-inflammatory Treatment and Cardiovascular Outcomes: Results of Clinical Trials. <i>European Cardiology Review</i> , 2021, 16, e15.	0.7	8
406	The effect of Vitamin-K1 and Colchicine on Vascular Calcification Activity in subjects with Diabetes Mellitus (ViKCoVaC): A double-blind 2x2 factorial randomized controlled trial. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1855-1866.	1.4	17
407	Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials. <i>Advances in Therapy</i> , 2021, 38, 2170-2200.	1.3	4
408	Inhibiting Interleukin-6 to Reduce Cardiovascular Event Rates. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1856-1858.	1.2	19
409	Statins in patients with acute ischemic stroke: when we should start therapy?. <i>Arterial Hypertension (Russian Federation)</i> , 2021, 27, 16-28.	0.1	4
410	Post-ischemic Myocardial Inflammatory Response: A Complex and Dynamic Process Susceptible to Immunomodulatory Therapies. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 647785.	1.1	28
411	Revisiting the Evidence for Dipyridamole in Reducing Restenosis: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 450-457.	0.8	2
412	Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation. <i>Nature Metabolism</i> , 2021, 3, 513-522.	5.1	34
413	Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1845-1855.	1.2	169
414	Different Approaches in Therapy Aiming to Stabilize an Unstable Atherosclerotic Plaque. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4354.	1.8	10
415	Coronary heart disease risk: Low-density lipoprotein and beyond. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 181-194.	2.3	56
416	Biomarkers of Inflammation and Risk of Hospitalization for Heart Failure in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2021, 10, e019168.	1.6	12
417	Clonal haematopoiesis of emerging significance. <i>Pathology</i> , 2021, 53, 300-311.	0.3	9
418	The association between treatment and systemic inflammation in acromegaly. <i>Growth Hormone and IGF Research</i> , 2021, 57-58, 101391.	0.5	6
419	IL-6 as a Mediator of the Association Between Traditional Risk Factors and Future Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1570-1579.	1.1	10
420	Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens. <i>Xenobiotica</i> , 2021, 51, 643-656.	0.5	19

#	ARTICLE	IF	CITATIONS
421	The clinical black, white, and gray lessons. <i>Current Opinion in Lipidology</i> , 2021, 32, 151-156.	1.2	1
422	Can a single genetic variant explain residual cardiovascular risk by modifying NLRP3 expression?. <i>European Heart Journal</i> , 2021, 42, 1757-1759.	1.0	1
423	Ablation of lysozyme M-positive cells prevents aircraft noise-induced vascular damage without improving cerebral side effects. <i>Basic Research in Cardiology</i> , 2021, 116, 31.	2.5	23
424	The Emerging Role of CT-Based Imaging in Adipose Tissue and Coronary Inflammation. <i>Cells</i> , 2021, 10, 1196.	1.8	12
425	Inflammation and Cardiovascular Disease: The Future. <i>European Cardiology Review</i> , 2021, 16, e20.	0.7	48
426	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2021, 42, 2630-2642.	1.0	69
427	White blood cell count and clinical outcomes after left main coronary artery revascularization. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, 45-51.	0.3	0
428	Coronary artery disease: "gout" in the artery?. <i>European Heart Journal</i> , 2021, 42, 2761-2764.	1.0	10
429	Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. <i>Circulation Research</i> , 2021, 128, 1728-1746.	2.0	238
430	Targeting inflammation in atherosclerosis "from experimental insights to the clinic. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 589-610.	21.5	459
431	Circulatory markers of immunity and carotid atherosclerotic plaque. <i>Atherosclerosis</i> , 2021, 325, 69-74.	0.4	12
432	Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1385-1392.	0.5	19
433	Contentious Issues in Gout Management: The Story so Far. <i>Open Access Rheumatology: Research and Reviews</i> , 2021, Volume 13, 111-122.	0.8	3
434	Observational Cross-Sectional Study of Inflammatory Markers After Transient Ischemic Attacks, Acute Coronary Syndromes, and Vascular Stroke Events. <i>CJC Open</i> , 2021, 3, 675-679.	0.7	0
436	Nonclassical Monocytes (CD14dimCD16+) Are Associated With Carotid Intima-Media Thickness Progression for Men but Not Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1810-1817.	1.1	10
437	Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 320, C902-C915.	2.1	22
438	Looking for the Achilles heel of atheromatosis: could it be immunotherapy?. <i>Immunotherapy</i> , 2021, 13, 557-560.	1.0	2
439	Lacunar stroke: mechanisms and therapeutic implications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 823-830.	0.9	27

#	ARTICLE	IF	CITATIONS
440	Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1915-1931.	1.6	21
441	IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2021, 397, 2060-2069.	6.3	268
442	Effects of Colchicine on Cardiovascular Outcomes in Patients with Coronary Artery Disease: A Systematic Review and One-Stage and Two-Stage Meta-Analysis of Randomized-Controlled Trials. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 343-354.	1.0	2
443	Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 641955.	1.3	6
444	Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment. <i>European Cardiology Review</i> , 2021, 16, e18.	0.7	31
445	Cardiovascular events and the role of accelerated atherosclerosis in systemic vasculitis. <i>Atherosclerosis</i> , 2021, 325, 8-15.	0.4	33
446	Inflammatory cytokines, high-sensitivity C-reactive protein, and risk of one-year vascular events, death, and poor functional outcome after stroke and transient ischemic attack. <i>International Journal of Stroke</i> , 2022, 17, 163-171.	2.9	23
447	Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome. <i>Journal of Internal Medicine</i> , 2021, 290, 392-403.	2.7	8
448	Canakinumab for secondary prevention of coronary artery disease. <i>Future Cardiology</i> , 2021, 17, 427-442.	0.5	10
449	Interplay between inflammation and thrombosis in cardiovascular pathology. <i>Nature Reviews Cardiology</i> , 2021, 18, 666-682.	6.1	337
450	The Fractalkine Receptor CX3CR1 Links Lymphocyte Kinetics in CMV-Seropositive Patients and Acute Myocardial Infarction With Adverse Left Ventricular Remodeling. <i>Frontiers in Immunology</i> , 2021, 12, 605857.	2.2	10
451	Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies. <i>Current Atherosclerosis Reports</i> , 2021, 23, 32.	2.0	11
452	Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects. <i>Atherosclerosis</i> , 2021, 324, 27-37.	0.4	25
453	Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 177-185.	1.5	8
454	Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction. <i>Open Heart</i> , 2021, 8, e001492.	0.9	4
455	Precision Medicine Approaches to Vascular Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2531-2550.	1.2	10
456	Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. <i>Nature Cancer</i> , 2021, 2, 527-544.	5.7	37
457	Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2). <i>Future Cardiology</i> , 2021, 17, 411-414.	0.5	10

#	ARTICLE	IF	CITATIONS
458	Multidisciplinary prevention and management strategies for colorectal cancer and cardiovascular disease. <i>European Journal of Internal Medicine</i> , 2021, 87, 3-12.	1.0	10
459	Colchicine and the heart. <i>European Heart Journal</i> , 2021, 42, 2745-2760.	1.0	84
460	Colchicine to Prevent Periprocedural Myocardial Injury in Percutaneous Coronary Intervention: The COPE-PCI Pilot Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009992.	1.4	27
461	Is Behçet's syndrome associated with an increased risk of ischemic heart disease? A real-world evidence in Taiwan. <i>Arthritis Research and Therapy</i> , 2021, 23, 161.	1.6	4
462	Prognostic value of pericoronary inflammation and unsupervised machine-learning-defined phenotypic clustering of CT angiographic findings. <i>International Journal of Cardiology</i> , 2021, 333, 226-232.	0.8	12
463	Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem. , 2021, 9, e002916.		29
464	Phosphorylcholine antibodies restrict infarct size and left ventricular remodelling by attenuating the unreperfused post-ischaemic inflammatory response. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7772-7782.	1.6	5
465	Safety and Efficacy of Colchicine in Patients with Stable CAD and ACS: A Systematic Review and Meta-analysis. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 659-668.	1.0	3
466	Monocyte-Chemoattractant Protein-1 Levels in Human Atherosclerotic Lesions Associate With Plaque Vulnerability. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2038-2048.	1.1	48
467	Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. <i>Pharmacological Reviews</i> , 2021, 73, 924-967.	7.1	359
468	Resilience of the Internal Mammary Artery to Atherogenesis: Shifting From Risk to Resistance to Address Unmet Needs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2237-2251.	1.1	16
469	Ca ²⁺ mishandling in heart failure: Potential targets. <i>Acta Physiologica</i> , 2021, 232, e13691.	1.8	11
470	Efficacy and Safety of Colchicine in Post-acute Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 676771.	1.1	6
471	Association between miR-146a and Tumor Necrosis Factor Alpha (TNF- α) in Stable Coronary Artery Disease. <i>Medicina (Lithuania)</i> , 2021, 57, 575.	0.8	4
472	Inflammation, atrial fibrillation, and the potential role for colchicine therapy. <i>Heart Rhythm O2</i> , 2021, 2, 298-303.	0.6	19
473	Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection. <i>Current Pharmaceutical Design</i> , 2021, 27, 2112-2130.	0.9	20
474	Inflammation during Percutaneous Coronary Intervention—Prognostic Value, Mechanisms and Therapeutic Targets. <i>Cells</i> , 2021, 10, 1391.	1.8	16
475	Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review). <i>Sovremennye Tehnologii V Medicine</i> , 2021, 13, 81.	0.4	4

#	ARTICLE	IF	CITATIONS
476	Infections as Novel Risk Factors of Atherosclerotic Cardiovascular Diseases: Pathophysiological Links and Therapeutic Implications. <i>Journal of Clinical Medicine</i> , 2021, 10, 2539.	1.0	16
477	Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials. <i>Open Heart</i> , 2021, 8, e001633.	0.9	1
478	Inflammation in heart disease: do researchers know enough?. <i>Nature</i> , 2021, 594, S8-S9.	13.7	3
479	How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. <i>Panminerva Medica</i> , 2022, 64, .	0.2	4
480	Homage to George E. Palade Cell Protein Secretion in Vascular Biology: Overview and Updates. <i>Acta Biologica Marisiensis</i> , 2021, 4, 31-43.	0.1	1
481	Optimal medical therapy after coronary artery bypass grafting: a primer for surgeons. <i>Current Opinion in Cardiology</i> , 2021, 36, 609-615.	0.8	6
482	The Use of Colchicine in Cardiovascular Diseases: A Systematic Review. <i>American Journal of Medicine</i> , 2021, 134, 735-744.e1.	0.6	12
483	Anti-Inflammatory Drugs in Patients with Ischemic Heart Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2835.	1.0	5
484	Molecular Imaging of Inflammation and Fibrosis in Pressure Overload Heart Failure. <i>Circulation Research</i> , 2021, 129, 369-382.	2.0	26
485	Oral pre-treatment with thiocyanate (SCN ⁻) protects against myocardial ischaemiaâ€“reperfusion injury in rats. <i>Scientific Reports</i> , 2021, 11, 12712.	1.6	11
486	Colchicine in Patients with Coronary Artery Disease with or Without Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials. <i>Clinical Drug Investigation</i> , 2021, 41, 667-674.	1.1	6
487	KLF4 Upregulation in Atherosclerotic Thoracic Aortas: Exploring the Protective Effect of Colchicine-based Regimens in a Hyperlipidemic Rabbit Model. <i>Annals of Vascular Surgery</i> , 2022, 78, 328-335.	0.4	5
488	Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharmaceutical Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6607.	1.8	50
489	Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) â€“ study protocol for a randomised controlled trial. <i>European Stroke Journal</i> , 2021, 6, 222-228.	2.7	45
490	The Role of Colchicine in Atherosclerotic Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2021, 30, 795-806.	0.2	12
491	Targeting Trained Innate Immunity With Nanobiologics to Treat Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1839-1850.	1.1	4
492	What Is the Clinical Impact of Stress CMR After the ISCHEMIA Trial?. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 683434.	1.1	13
493	Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease. <i>Nature Communications</i> , 2021, 12, 3754.	5.8	39

#	ARTICLE	IF	CITATIONS
494	LuQi Formula Regulates NLRP3 Inflammasome to Relieve Myocardial-Infarction-Induced Cardiac Remodeling in Mice. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-14.	0.5	6
495	Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. Platelets, 2022, 33, 425-431.	1.1	9
497	Managing dyslipidemia in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy, 2021, 22, 2221-2234.	0.9	14
498	Immunotherapy and cardiovascular diseases: novel avenues for immunotherapeutic approaches. QJM - Monthly Journal of the Association of Physicians, 2023, 116, 271-278.	0.2	5
499	Percutaneous Coronary Revascularization. Journal of the American College of Cardiology, 2021, 78, 384-407.	1.2	16
500	Effect of anti-inflammatory therapy on major cardiovascular events in patients with diabetes: A meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102164.	1.8	5
501	Long-term outcomes of patients with chronic inflammatory diseases after percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, 98, E655-E660.	0.7	4
502	Comparative EPR Study on the Scavenging Effect of Methotrexate with the Isomers of Its Photoswitchable Derivative. Pharmaceuticals, 2021, 14, 665.	1.7	2
503	Anti-inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy. Journal of Cellular and Molecular Medicine, 2021, 25, 8087-8094.	1.6	14
504	Metabolic regulation of macrophage proliferation and function in atherosclerosis. Current Opinion in Lipidology, 2021, 32, 293-300.	1.2	5
505	The Role of C-reactive Protein in Patient Risk Stratification and Treatment. European Cardiology Review, 2021, 16, e28.	0.7	7
506	Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study. PLoS ONE, 2021, 16, e0253932.	1.1	9
508	Immune cell profiling in atherosclerosis: role in research and precision medicine. Nature Reviews Cardiology, 2022, 19, 43-58.	6.1	58
509	Downhill hiking improves low-grade inflammation, triglycerides, body weight and glucose tolerance. Scientific Reports, 2021, 11, 14503.	1.6	6
510	Treating Acute Myocardial Infarctions With Anti-Inflammatory Agents. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 736-738.	1.0	1
511	Relative Predictive Value of Circulating Immune Markers in US Adults Without Cardiovascular Disease: Implications for Risk Reclassification. Mayo Clinic Proceedings, 2021, 96, 1812-1821.	1.4	5
512	An Updated Meta-Analysis of RCTs of Colchicine for Stroke Prevention in Patients with Coronary Artery Disease. Journal of Clinical Medicine, 2021, 10, 3110.	1.0	5
513	Effect of Colchicine in Reducing Inflammatory Biomarkers and Cardiovascular Risk in Coronary Artery Disease: A Meta-analysis of Clinical Trials. American Journal of Therapeutics, 2023, 30, e197-e208.	0.5	3

#	ARTICLE	IF	CITATIONS
514	New insight into biology, molecular diagnostics and treatment options of unstable carotid atherosclerotic plaque: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 1207-1207.	0.7	16
515	Frailty is associated with chronic inflammation and pro-inflammatory monocyte subpopulations. <i>Experimental Gerontology</i> , 2021, 149, 111317.	1.2	14
516	Pharmacological secondary prevention of MI. <i>The Prescriber</i> , 2021, 32, 13-20.	0.1	0
517	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). <i>Archivos De Cardiologia De Mexico</i> , 2021, 82, .	0.1	4
518	2021 Update for the Diagnosis and Management of Acute Coronary Syndromes for the Perioperative Clinician. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, , .	0.6	2
519	PET Imaging of Post-infarct Myocardial Inflammation. <i>Current Cardiology Reports</i> , 2021, 23, 99.	1.3	4
520	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 181-264.	0.3	45
521	Effect of Liraglutide on Arterial Inflammation Assessed as [¹⁸ F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e012174.	1.3	18
522	Activation of Aryl Hydrocarbon Receptor by ITE Improves Cardiac Function in Mice After Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021, 10, e020502.	1.6	9
523	Causal Associations of Urate With Cardiovascular Risk Factors: Two-Sample Mendelian Randomization. <i>Frontiers in Genetics</i> , 2021, 12, 687279.	1.1	8
524	Analysis of Immune Associated Co-Expression Networks Reveals Immune-Related Long Non-Coding RNAs during MI in the Presence and Absence of HDC. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7401.	1.8	2
525	The challenge of choosing in cardiovascular risk management. <i>Netherlands Heart Journal</i> , 2022, 30, 47-57.	0.3	5
526	Colchicine in the Management of Acute and Chronic Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2021, 23, 120.	1.3	3
527	Immune-based therapies in cardiovascular and metabolic diseases: past, present and future. <i>Nature Reviews Immunology</i> , 2021, 21, 669-679.	10.6	16
528	Association of neutrophil-to-lymphocyte ratio with non-calcified coronary artery burden in psoriasis: Findings from an observational cohort study. <i>Journal of Cardiovascular Computed Tomography</i> , 2021, 15, 372-379.	0.7	17
529	Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation. <i>Pharmacological Research</i> , 2021, 169, 105689.	3.1	29
530	Randomized comparison between bare-metal stent plus colchicine versus drug-eluting stent alone in prevention of clinical adverse events after percutaneous coronary intervention. <i>Future Cardiology</i> , 2021, 17, 539-547.	0.5	0
531	Predictive value of inflammation-based Glasgow prognostic score, platelet-lymphocyte ratio, and global registry of acute coronary events score for major cardiovascular and cerebrovascular events during hospitalization in patients with acute myocardial infarction. <i>Aging</i> , 2021, 13, 18274-18286.	1.4	10

#	ARTICLE	IF	CITATIONS
532	Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 143.	2.7	22
533	WBC count predicts heart failure in diabetes and coronary artery disease patients: a retrospective cohort study. <i>ESC Heart Failure</i> , 2021, 8, 3748-3759.	1.4	17
534	Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies. <i>JACC Basic To Translational Science</i> , 2021, 6, 610-623.	1.9	47
535	Persistent Lung Inflammation After Clinical Resolution of Community-Acquired Pneumonia as Measured by 18FDG-PET/CT Imaging. <i>Chest</i> , 2021, 160, 446-453.	0.4	9
536	Pharmacotherapy of gout – modern approaches and prospects. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 107-112.	0.1	1
537	Diabetes mellitus is independently associated with early stent thrombosis in patients undergoing drug eluting stent implantation: Analysis from the Victorian cardiac outcomes registry. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 554-562.	0.7	9
538	The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. <i>European Heart Journal</i> , 2021, 42, 4389-4400.	1.0	61
539	How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. <i>Nature Reviews Immunology</i> , 2022, 22, 251-265.	10.6	176
540	Role of inflammation and immunity in atherosclerosis and possible ways of their control. <i>Vnitřní Lekarství</i> , 2021, 67, 304-308.	0.1	0
541	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1837-1845.	0.8	8
542	Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial. <i>Inflammopharmacology</i> , 2021, 29, 1379-1387.	1.9	23
543	Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e021198.	1.6	31
544	Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms. <i>Current Cardiology Reviews</i> , 2022, 18, .	0.6	3
545	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
546	Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1175-1186.	1.3	7
547	Anti-inflammatory Therapies for Coronary Heart Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 726341.	1.1	6
548	Gout plus cardiovascular disease is painful, but treatable. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 407-414.	0.3	1
549	Molecular imaging of cardiovascular inflammation. <i>British Journal of Pharmacology</i> , 2021, 178, 4216-4245.	2.7	5

#	ARTICLE	IF	CITATIONS
550	Prevalence and Extent of Subclinical Atherosclerosis and Associated Cardiovascular Risk Factors in Adult Patients With Psoriatic Arthritis: A Systematic Review. <i>Cureus</i> , 2021, 13, e16853.	0.2	4
551	Glucocorticoid induced TNF receptor family-related protein (GITR) – A novel driver of atherosclerosis. <i>Vascular Pharmacology</i> , 2021, 139, 106884.	1.0	3
552	A narrative review of plaque and brain imaging biomarkers for stroke risk stratification in patients with atherosclerotic carotid artery disease. <i>Annals of Translational Medicine</i> , 2021, 9, 1260-1260.	0.7	4
553	Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial. <i>International Journal of Cardiology</i> , 2021, 337, 21-27.	0.8	19
554	Perivascular Adipose Tissue Attenuation on Computed Tomography beyond the Coronary Arteries. A Systematic Review. <i>Diagnostics</i> , 2021, 11, 1495.	1.3	6
555	Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models. <i>Molecules</i> , 2021, 26, 4996.	1.7	15
556	Anti-inflammatory activity of the Tongmai Yangxin pill in the treatment of coronary heart disease is associated with estrogen receptor and NF- κ B signaling pathway. <i>Journal of Ethnopharmacology</i> , 2021, 276, 114106.	2.0	26
557	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. <i>JAMA Cardiology</i> , 2021, 6, 1440.	3.0	43
558	Redefining residual inflammatory risk after acute coronary syndrome. <i>Future Cardiology</i> , 2022, 18, 115-123.	0.5	2
559	Carotid Atheroinflammation Is Associated With Cerebral Small Vessel Disease Severity. <i>Frontiers in Neurology</i> , 2021, 12, 690935.	1.1	6
560	Targeting epigenetic modifiers to reprogramme macrophages in non-resolving inflammation-driven atherosclerosis. <i>European Heart Journal Open</i> , 2021, 1, .	0.9	9
561	Inflammation and ischemic heart disease: The next therapeutic target?. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 785-796.	0.2	9
562	Cardiovascular disease in diabetes, beyond glucose. <i>Cell Metabolism</i> , 2021, 33, 1519-1545.	7.2	87
563	Targeting residual inflammatory risk in coronary disease: to catch a monkey by its tail. <i>Netherlands Heart Journal</i> , 2022, 30, 25-37.	0.3	3
564	DNA methylome profiling reveals epigenetic regulation of lipoprotein-associated phospholipase A2 in human vulnerable atherosclerotic plaque. <i>Clinical Epigenetics</i> , 2021, 13, 161.	1.8	16
565	Single cell analyses to understand the immune continuum in atherosclerosis. <i>Atherosclerosis</i> , 2021, 330, 85-94.	0.4	18
566	Chronic low-grade inflammation in heart failure with preserved ejection fraction. <i>Aging Cell</i> , 2021, 20, e13453.	3.0	33
567	Colchicine-Containing Nanoparticles Attenuates Acute Myocardial Infarction Injury by Inhibiting Inflammation. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1075-1089.	1.3	17

#	ARTICLE	IF	CITATIONS
568	Postnatal inflammation in <i>ApoE^{-/-}</i> mice is associated with immune training and atherosclerosis. <i>Clinical Science</i> , 2021, 135, 1859-1871.	1.8	3
569	Colchicine administration for percutaneous coronary intervention: A meta-analysis of randomized controlled trials. <i>American Journal of Emergency Medicine</i> , 2021, 46, 121-125.	0.7	1
570	Low-Dose Colchicine in Coronary Artery Disease – Systematic Review and Meta-Analysis. <i>Circulation Reports</i> , 2021, 3, 457-464.	0.4	6
571	Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2021, 78, 859-866.	1.2	27
572	Resident Macrophages and Their Potential in Cardiac Tissue Engineering. <i>Tissue Engineering - Part B: Reviews</i> , 2022, 28, 579-591.	2.5	12
573	Distinct pathological mechanisms distinguish acute coronary syndrome caused by plaque erosion from plaque rupture. <i>Current Opinion in Cardiology</i> , 2021, 36, 793-797.	0.8	2
574	Hyperuricemia in Patients With Coronary Artery Disease and Its Association With Disease Severity. <i>Cureus</i> , 2021, 13, e17161.	0.2	3
575	Low-Dose Colchicine for the Management of Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 78, 867-869.	1.2	1
576	Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial. <i>Contemporary Clinical Trials</i> , 2021, 110, 106547.	0.8	4
577	Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. <i>American Journal of Medicine</i> , 2022, 135, 32-38.	0.6	41
578	Human coronary inflammation by computed tomography: Relationship with coronary microvascular dysfunction. <i>International Journal of Cardiology</i> , 2021, 336, 8-13.	0.8	14
579	Inflammation and Stroke Risk: A New Target for Prevention. <i>Stroke</i> , 2021, 52, 2697-2706.	1.0	78
580	Prognostic Value of RCA Pericoronary Adipose Tissue CT-Attenuation Beyond High-Risk Plaques, Plaque Volume, and Ischemia. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1598-1610.	2.3	43
581	Impact of high neutrophil-to-lymphocyte ratio on the cardiovascular benefit of PCSK9 inhibitors in familial hypercholesterolemia subjects with atherosclerotic cardiovascular disease: Real-world data from two lipid units. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 3401-3406.	1.1	10
582	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 924-932.	5.2	218
583	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	0.8	220
584	High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a). <i>Journal of the American College of Cardiology</i> , 2021, 78, 1083-1094.	1.2	60
585	Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1211-1228.	1.1	1

#	ARTICLE	IF	CITATIONS
586	Selective Cdk9 inhibition resolves neutrophilic inflammation and enhances cardiac regeneration in larval zebrafish. <i>Development (Cambridge)</i> , 2022, 149, .	1.2	10
587	Telomere Attrition and Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9867.	1.8	5
588	Hydrogel-load exosomes derived from dendritic cells improve cardiac function via Treg cells and the polarization of macrophages following myocardial infarction. <i>Journal of Nanobiotechnology</i> , 2021, 19, 271.	4.2	47
589	La prÃ©vention secondaire mÃ©dicamenteuse en pathologie neuro-vasculaire a-t-elle des spÃ©cificitÃ©s?. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2021, 205, 1091-1091.	0.0	0
590	COLchicine to Prevent Periprocedural myocardial Injury in Percutaneous Coronary Intervention (COPE-PCI): A Descriptive Cytokine Pilot Sub-Study. <i>Cardiovascular Revascularization Medicine</i> , 2021, , .	0.3	6
591	Persistent inflammatory residual risk despite aggressive cholesterol-lowering therapy. <i>Current Opinion in Cardiology</i> , 2021, Publish Ahead of Print, 776-783.	0.8	1
592	Bayesian Analyses of Cardiovascular Trialsâ€”Bringing Added Value to the Table. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1415-1427.	0.8	3
593	Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction. <i>Lipids in Health and Disease</i> , 2021, 20, 124.	1.2	3
594	Pre-Operative Plasma Extracellular Vesicle Proteins are Associated with a High Risk of Long Term Secondary Major Cardiovascular Events in Patients Undergoing Carotid Endarterectomy. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 62, 705-715.	0.8	5
595	Tryptophan: From Diet to Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9904.	1.8	24
596	Impact of Acute and Chronic Psychosocial Stress on Vascular Inflammation. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 1531-1550.	2.5	20
597	Increased Vulnerability and Distinct Layered Phenotype at Culprit and Nonculprit Lesions in STEMI Versus NSTEMI. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 672-681.	2.3	15
598	Clonal Hematopoiesis of Indeterminate Potential: an Expanding Genetic Cause of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2021, 23, 66.	2.0	7
599	Inflammation during the life cycle of the atherosclerotic plaque. <i>Cardiovascular Research</i> , 2021, 117, 2525-2536.	1.8	69
600	Role of extracellular vesicles in atherosclerosis: An update. <i>Journal of Leukocyte Biology</i> , 2021, 111, 51-62.	1.5	19
601	SÃ©ndrome coronario en pacientes con comorbilidades. <i>Medicine</i> , 2021, 13, 2190-2198.	0.0	0
602	Colchicine Use and Risks of Stroke Recurrence in Acute Non-Cardiogenic Ischemic Stroke Patients: A Population-Based Cohort Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 935.	1.1	5
603	Emerging agents for the treatment and prevention of stroke: progress in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1025-1035.	1.9	13

#	ARTICLE	IF	CITATIONS
604	Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. <i>Circulation</i> , 2021, 144, 859-869.	1.6	74
605	The inflammatory state is a risk factor for cardiovascular disease and graft fibrosis in kidney transplantation. <i>Kidney International</i> , 2021, 100, 536-545.	2.6	17
606	Antithrombotic therapy in high-risk patients after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events. <i>Netherlands Heart Journal</i> , 2021, 29, 525-535.	0.3	2
607	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 41.	1.7	15
608	Incomplete Recovery From Takotsubo Syndrome Is a Major Determinant of Cardiovascular Mortality. <i>Circulation Journal</i> , 2021, 85, 1823-1831.	0.7	8
609	Interleukin-1 β Is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease. <i>Circulation</i> , 2021, 144, 893-908.	1.6	36
610	Possibilities and perspectives of colchicine application in complex therapy in patients with COVID-19. <i>Klinicheskaia Meditsina</i> , 2021, 99, 165-171.	0.2	0
611	Colchicine reduces atherosclerotic plaque vulnerability in rabbits. <i>Atherosclerosis Plus</i> , 2021, 45, 1-9.	0.3	6
612	The effectiveness of early colchicine administration in patients over 60 years old with high risk of developing severe pulmonary complications associated with coronavirus pneumonia SARS-CoV-2 (COVID-19): study protocol for an investigator-driven randomized controlled clinical trial in primary health care – COLCHICOVID study. <i>Trials</i> , 2021, 22, 590.	0.7	4
613	Inflammation and Comorbidity. Are There any Chances to Improve the Prognosis in Patients with Extremely High Cardiovascular Risk?. <i>Rational Pharmacotherapy in Cardiology</i> , 2021, 17, 606-611.	0.3	2
614	High triglyceride to HDL cholesterol ratio is associated with increased coronary heart disease among White but not Black adults. <i>American Journal of Preventive Cardiology</i> , 2021, 7, 100198.	1.3	8
615	Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. <i>International Journal of Women's Dermatology</i> , 2021, 7, 560-575.	1.1	7
616	Repurposing Colchicine for Heart Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 121-129.	4.2	8
617	Stroke Genetics: Turning Discoveries into Clinical Applications. <i>Stroke</i> , 2021, 52, 2974-2982.	1.0	9
618	De novo Drug Delivery Modalities for Treating Damaged Hearts: Current Challenges and Emerging Solutions. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 742315.	1.1	2
619	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction – findings from the LATITUDE – TIMI 60 trial. <i>American Heart Journal</i> , 2022, 243, 147-157.	1.2	5
620	Dose-Dependent Association of Inflammatory Cytokines with Carotid Atherosclerosis in Transient Ischaemic Attack: Implications for Clinical Trials. <i>Cerebrovascular Diseases</i> , 2022, 51, 178-187.	0.8	6
621	Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1520-1528.	1.1	17

#	ARTICLE	IF	CITATIONS
622	Pericoronary adipose tissue attenuation by computed tomography: A novel indicator for coronary microvascular dysfunction?. <i>International Journal of Cardiology</i> , 2021, 343, 12-13.	0.8	0
623	Pericarditis following acute coronary syndrome: epidemiology and treatment. <i>Internal and Emergency Medicine</i> , 2021, , 1.	1.0	0
624	The role and transformative potential of IL-19 in atherosclerosis. <i>Cytokine and Growth Factor Reviews</i> , 2021, 62, 70-82.	3.2	9
625	miR-24 alleviates MI/RI by blocking the S100A8/TLR4/MyD88/NF- κ B pathway. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, 847-857.	0.8	3
626	New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2328-2337.	0.3	21
627	Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy. <i>Atherosclerosis</i> , 2021, 334, 93-100.	0.4	25
628	Management of inflammation in cardiovascular diseases. <i>Pharmacological Research</i> , 2021, 173, 105912.	3.1	39
629	The association of air pollutants exposure with subclinical inflammation and carotid atherosclerosis. <i>International Journal of Cardiology</i> , 2021, 342, 108-114.	0.8	8
631	Inflammatory markers in acute myocardial infarction and the correlation with the severity of coronary heart disease. <i>Annals of Medicine</i> , 2021, 53, 1042-1048.	1.5	24
632	Medications for gout and its comorbidities: mutual benefits?. <i>Current Opinion in Rheumatology</i> , 2021, 33, 145-154.	2.0	2
633	Atherosclerosis is a major human killer and non-resolving inflammation is a prime suspect. <i>Cardiovascular Research</i> , 2021, 117, 2563-2574.	1.8	18
634	Lipoproteins in chronic kidney disease: from bench to bedside. <i>European Heart Journal</i> , 2021, 42, 2170-2185.	1.0	32
635	Colchicine administered early in acute myocardial infarction: ready, set & go?. <i>European Heart Journal</i> , 2021, 42, 2802-2802.	1.0	5
636	Acute Myocardial Infarction in Systemic Mastocytosis: Case Report With Literature Review on the Role of Inflammatory Process in Acute Coronary Syndrome. <i>Current Cardiology Reviews</i> , 2021, 16, 333-337.	0.6	5
637	Targeting the Vascular Endothelium in the Treatment of COVID-19. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 1-3.	0.8	4
638	Lessons from COLCOT and LoDoCo2: colchicine for secondary prevention in coronary artery disease. <i>European Heart Journal</i> , 2021, 42, 2800-2801.	1.0	7
639	Colchicine and the heart: old friends, old foes. <i>Rheumatology</i> , 2021, 60, 2035-2036.	0.9	3
640	Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen?. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2021, 15, 175394472110427.	1.0	0

#	ARTICLE	IF	CITATIONS
641	Comparative Effectiveness of Anti-Inflammatory Drug Treatments in Coronary Heart Disease Patients: A Systematic Review and Network Meta-Analysis. <i>Mediators of Inflammation</i> , 2021, 2021, 1-17.	1.4	10
642	Biodegradable Synthetic Polymer Based Cardiac Patches: A Journey so far. , 2021, , .		0
643	The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. <i>European Heart Journal</i> , 2021, 42, 896-903.	1.0	152
644	Prognostic and therapeutic considerations of antibodies against C-reactive protein in the general population. <i>Clinical and Translational Immunology</i> , 2020, 9, e1220.	1.7	6
645	Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 499-512.	1.0	21
646	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. <i>Atherosclerosis</i> , 2020, 296, 40-47.	0.4	78
647	Phosphorylcholine Antibodies Preserve Cardiac Function and Reduce Infarct Size by Attenuating the Post-Ischemic Inflammatory Response. <i>JACC Basic To Translational Science</i> , 2020, 5, 1228-1239.	1.9	8
648	Clinical approach to the inflammatory etiology of cardiovascular diseases. <i>Pharmacological Research</i> , 2020, 159, 104916.	3.1	56
649	Inflammation in Atherosclerosis—No Longer a Theory. <i>Clinical Chemistry</i> , 2021, 67, 131-142.	1.5	158
650	Colchicine in coronary disease: another renaissance of an ancient drug. <i>Cardiovascular Research</i> , 2021, 117, e4-e6.	1.8	2
651	Colchicine therapy in patients with coronary artery disease. <i>Coronary Artery Disease</i> , 2020, Publish Ahead of Print, 441-447.	0.3	9
656	Impact of sex and gender on COVID-19 outcomes in Europe. <i>Biology of Sex Differences</i> , 2020, 11, 29.	1.8	832
657	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. <i>PLoS ONE</i> , 2020, 15, e0242318.	1.1	28
658	PROSPECTS FOR USING COLCHICINE IN MEDICINE: NEW EVIDENCE. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 183-190.	0.2	10
660	Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets. <i>Current Pharmaceutical Design</i> , 2020, 26, 2565-2573.	0.9	22
661	Pro-inflammatory Cytokines in Acute Coronary Syndromes. <i>Current Pharmaceutical Design</i> , 2020, 26, 4624-4647.	0.9	23
662	Increased incidence of serious late adverse events with drug-eluting stents when compared with coronary artery bypass surgery: a cause of concern. <i>Future Cardiology</i> , 2020, 16, 711-723.	0.5	4
663	COLCOT and CANTOS: piecing together the puzzle of inflammation and cardiovascular events. <i>Minerva Cardioangiologica</i> , 2020, 68, 5-8.	1.2	5

#	ARTICLE	IF	CITATIONS
664	Beyond the lung involvement in COVID-19 patients. <i>Minerva Medica</i> , 2022, 113, .	0.3	17
665	Imaging inflammation in cardiovascular disease: translational perspective and overview. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 1-3.	0.4	3
666	Colchicine for the treatment of cardiovascular diseases: old drug, new targets. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 1-8.	0.6	20
667	Sex and Gender Differences in Heart Failure. <i>International Journal of Heart Failure</i> , 2020, 2, 157.	0.9	43
668	Aterosclerose e Inflama��o: Ainda Muito Caminho a Percorrer. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 114, 699-700.	0.3	4
669	SARS-CoV-2 and myocardial injury: Few answers, many questions. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 521-525.	0.6	13
670	Investigating pleiotropic effects of statins on ischemic heart disease in the UK Biobank using Mendelian randomisation. <i>ELife</i> , 2020, 9, .	2.8	27
671	Reprogramming of bone marrow myeloid progenitor cells in patients with severe coronary artery disease. <i>ELife</i> , 2020, 9, .	2.8	23
672	Interleukin-1�2 suppression dampens inflammatory leucocyte production and uptake in atherosclerosis. <i>Cardiovascular Research</i> , 2022, 118, 2778-2791.	1.8	47
673	Therapeutic perspectives of extracellular vesicles and extracellular microRNAs in atherosclerosis. <i>Current Topics in Membranes</i> , 2021, 87, 255-277.	0.5	5
674	Apolipoprotein A-I for Cardiac Recovery Post�� Myocardial Infarction. <i>JACC Basic To Translational Science</i> , 2021, 6, 768-771.	1.9	2
675	Colchicine to Prevent Sympathetic Denervation after an Acute Myocardial Infarction: The COLD-MI Trial Protocol. <i>Medicina (Lithuania)</i> , 2021, 57, 1047.	0.8	3
676	NLRP3 Inflammasome in Cardiovascular Disease: David's Stone against Goliath?. <i>Revista Romana De Cardiologie</i> , 2021, 31, 517-527.	0.0	1
677	Inflammatory hypothesis of atherogenesis: Will colchicine be added to the armamentarium in the prevention of coronary artery disease?. <i>American Heart Journal Plus</i> , 2021, 9, 100057.	0.3	0
678	Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine. <i>European Heart Journal Supplements</i> , 2021, 23, E13-E18.	0.0	10
679	Trans-Myocardial Blood Interleukin-6 Levels Relate to Intracoronary Imaging-Defined Features of Plaque Vulnerability and Predict Procedure-Induced Myocardial Infarction. <i>Cardiovascular Revascularization Medicine</i> , 2022, 39, 6-11.	0.3	4
680	Colchicine for cardiovascular therapy: A drug interaction perspective and a safety meta-analysis. , 2021, 25, 753-761.		5
681	Obesity and Cardiovascular Disease: The Emerging Role of Inflammation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 768119.	1.1	24

#	ARTICLE	IF	CITATIONS
682	Colchicine â€œ new horizons for an ancient drug. Review based on the highest hierarchy of evidence. <i>European Journal of Internal Medicine</i> , 2022, 96, 34-41.	1.0	13
683	Carotid Plaque Inflammation Imaged by PET and Prediction of Recurrent Stroke at 5 Years. <i>Neurology</i> , 2021, 97, e2282-e2291.	1.5	14
684	Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective. <i>Cardiovascular Research</i> , 2021, 117, 2589-2609.	1.8	25
685	Similar Inflammatory Biomarkers Reflect Different Platelet Reactivity in Percutaneous Coronary Intervention Patients Treated With Clopidogrel: A Large-Sample Study From China. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 736466.	1.1	6
686	Association Between Stent Implantation and Progression of Nontarget Lesions in a Rabbit Model of Atherosclerosis. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010764.	1.4	11
687	Neutrophil extracellular traps: from physiology to pathology. <i>Cardiovascular Research</i> , 2022, 118, 2737-2753.	1.8	96
688	Anti-Inflammatory Therapeutics and Coronary Artery Disease. <i>Cardiology in Review</i> , 2021, Publish Ahead of Print, .	0.6	1
689	Colchicine â€” From rheumatology to the new kid on the block: Coronary syndromes and COVID-19. <i>Cardiology Journal</i> , 2023, 30, 297-311.	0.5	5
690	CXCR4-Targeted Imaging of Post-Infarct Myocardial Tissue Inflammation. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 372-374.	2.3	17
691	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2021. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, , .	0.6	1
692	Randomized Trial of Anti-inflammatory Medications and Coronary Endothelial Dysfunction in Patients With Stable Coronary Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 728654.	1.1	3
693	Immune cell subsets as a marker of development of heart failure: The application of bioinformatics tools. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 849-849.	0.2	0
694	The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis. <i>Trends in Molecular Medicine</i> , 2021, 27, 1095-1105.	3.5	17
695	Interleukin 6 trans-signalling and the risk of future cardiovascular events in men and women. <i>Open Heart</i> , 2021, 8, e001694.	0.9	6
696	Association Between Colchicine Treatment and Clinical Outcomes in Patients with Coronary Artery Disease: Systematic Review and Meta-analysis. <i>European Cardiology Review</i> , 2021, 16, e39.	0.7	4
697	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1419-1426.	5.2	123
698	Inflammatory Mediators of Platelet Activation: Focus on Atherosclerosis and COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11170.	1.8	34
699	Stamp2 Protects From Maladaptive Structural Remodeling and Systolic Dysfunction in Post-Ischemic Hearts by Attenuating Neutrophil Activation. <i>Frontiers in Immunology</i> , 2021, 12, 701721.	2.2	0

#	ARTICLE	IF	CITATIONS
700	Colchicine et syndromes coronariens aigus et chroniques. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2021, 2021, 7-10.	0.0	0
701	Colchicine for Coronary Heart Disease: A Meta-Analysis of Randomized Controlled Trials. Heart Surgery Forum, 2021, 24, E863-E867.	0.2	2
702	S�ndrome Coron�ria Aguda em Mulheres Idosas: A Inflama�o Ataca Novamente. Arquivos Brasileiros De Cardiologia, 2020, 114, 515-517.	0.3	1
703	Lipidsenkende Mittel. , 2020, , 601-614.		0
706	Old drug, new trick: colchicine for cardiovascular diseases. Journal of the Royal College of Physicians of Edinburgh, The, 2020, 50, 49-50.	0.2	0
707	Predictive value of three Inflammation-based Glasgow Prognostic Scores for major cardiovascular adverse events in patients with acute myocardial infarction during hospitalization: a retrospective study. PeerJ, 2020, 8, e9068.	0.9	8
708	Is There a Role for Colchicine in Acute Coronary Syndromes? A Literature Review. Cureus, 2020, 12, e8166.	0.2	5
709	Future challenges. , 2020, , 287-299.		0
710	Clinical discussion: gout therapy in a comorbid patient. Meditsinskiy Sovet, 2020, , 154-162.	0.1	0
711	Calcium pyrophosphate deposition (CPPD) disease � Treatment options. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101720.	1.4	8
712	Improvements in High-Density Lipoprotein Quantity and Quality Contribute to the Cardiovascular Benefits by Anti-tumor Necrosis Factor Therapies in Rheumatoid Arthritis: A Systemic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 765749.	1.1	5
713	The Role of the Inflammasome in Heart Failure. Frontiers in Physiology, 2021, 12, 709703.	1.3	29
714	Editorial: The 2021 European Society of Cardiology (ESC) Guidelines on the Real-World Prevention of Atherosclerotic Cardiovascular Disease (ASCVD). Medical Science Monitor, 2021, 27, e935172.	0.5	4
715	Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine. Journal of Clinical Medicine, 2021, 10, 5128.	1.0	2
716	Relationship of Serial High-Sensitivity C-Reactive Protein Changes to Long-term Clinical Outcomes in Stabilised Patients After Myocardial Infarction. Canadian Journal of Cardiology, 2022, 38, 92-101.	0.8	4
717	Personalized Therapy of Cardiovascular Disorders. , 2021, , 279-316.		0
718	Use of cardiovascular imaging in risk restratification of the diabetic patient. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 122-133.	1.2	2
719	Inflammation and Atherosclerotic Cardiovascular Disease. Contemporary Cardiology, 2021, , 289-333.	0.0	0

#	ARTICLE	IF	CITATIONS
720	The Role of Colchicine in Acute Coronary Syndrome. Heart Science Journal, 2020, 1, 4-8.	0.0	0
721	Acute Coronary Syndrome Developed in a 17-year-old Boy with Sitosterolemia Comorbid with Takayasu Arteritis: A Rare Case Report and Review of the Literature. Internal Medicine, 2022, 61, 1169-1177.	0.3	4
722	MÃ©dicaments des maladies inflammatoires systÃ©miques, auto-immunes et rhumatismales. , 2020, , 25-78.		0
723	Acute coronary syndrome: how to reduce the residual inflammatory risk?. Russian Journal of Cardiology, 2020, 25, 113-118.	0.4	3
724	The year in cardiology: cardiovascular prevention. The year in cardiology 2019.. SA Heart Journal, 2020, 17, .	0.0	0
726	Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes. Journal of Thrombosis and Thrombolysis, 2022, 53, 739-749.	1.0	5
727	Design of a Randomized Placebo-Controlled Trial to Evaluate the Anti-inflammatory and Senolytic Effects of Quercetin in Patients Undergoing Coronary Artery Bypass Graft Surgery. Frontiers in Cardiovascular Medicine, 2021, 8, 741542.	1.1	10
728	Colchicine in Patients With Acute Coronary Syndrome: Two-Year Follow-Up of the Australian COPS Randomized Clinical Trial. Circulation, 2021, 144, 1584-1586.	1.6	16
729	Causes of Death in People With Cardiovascular Disease: A UK Biobank Cohort Study. Journal of the American Heart Association, 2021, 10, e023188.	1.6	13
730	Targeting the Inflammasome in Cardiovascular Disease. JACC Basic To Translational Science, 2022, 7, 84-98.	1.9	53
731	Clinical features and mechanistic insights into drug repurposing for combating COVID-19. International Journal of Biochemistry and Cell Biology, 2022, 142, 106114.	1.2	12
732	Low Pain Tolerance Is Associated With Coronary Angiography, Coronary Artery Disease, and Mortality: The TromsÃ© Study. Journal of the American Heart Association, 2021, 10, e021291.	1.6	3
733	Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects. International Journal of General Medicine, 2021, Volume 14, 7797-7805.	0.8	2
735	Inflammation in Cardiovascular Disease: From Basic Concepts to Clinical Application. International Journal of Cardiovascular Sciences, 2020, , .	0.0	0
736	Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives. Cardiac Failure Review, 2020, 6, e24.	1.2	3
738	Current and future use of colchicine in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 71-74.	0.2	2
739	Stable Ischemic Heart Disease. , 2021, , 125-154.		0
740	Assessment of cardiovascular risk in patients with crystal-induced arthritides and rheumatoid arthritis by the ATP III and Reynolds Risk Score. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 512-519.	0.2	5

#	ARTICLE	IF	CITATIONS
741	By half decrease of cardiovascular mortality in a Western country between 2000 and 2015: A contrasted picture advocating for a better management of comorbidities. <i>International Journal of Cardiology</i> , 2020, 318, 145-146.	0.8	0
742	oxLDL-Induced Trained Immunity Is Dependent on Mitochondrial Metabolic Reprogramming. <i>Immunometabolism</i> , 2021, 3, e210025.	6.0	7
743	Updates in Psoriasis Management: Based on selected presentations from Maui Derm 2020, January 25-29, 2020, Maui, Hawaii. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2020, 13, S1-S17.	0.1	1
744	Intra-Coronary Administration of Tacrolimus Improves Myocardial Perfusion and Left Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction (COAT-STEMI) Undergoing Primary Percutaneous Coronary Intervention. <i>Acta Cardiologica Sinica</i> , 2021, 37, 239-253.	0.1	0
745	Inflammation Post-Acute Myocardial Infarction: "Doctor or Monster". <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 1112-1113.	0.3	1
746	Immune cells in cardiac homeostasis and disease: emerging insights from novel technologies. <i>European Heart Journal</i> , 2022, 43, 1533-1541.	1.0	33
747	Anti-inflammatory Therapy in Atherosclerosis: The Past and the Future. <i>Cardiology Discovery</i> , 2021, 1, 12-14.	0.6	2
748	Microvascular Ageing Links Metabolic Disease to Age-Related Disorders: The Role of Oxidative Stress and Inflammation in Promoting Microvascular Dysfunction. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, S78-S87.	0.8	17
749	Inflammation and ischemic heart disease: The next therapeutic target?. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 785-796.	0.2	5
751	Immunomodulatory drug discovery from herbal medicines: Insights from organ-specific activity and xenobiotic defenses. <i>ELife</i> , 2021, 10, .	2.8	16
752	FOXC2 Alleviates Myocardial Ischemia-Reperfusion Injury in Rats through Regulating Nrf2/HO-1 Signaling Pathway. <i>Disease Markers</i> , 2021, 2021, 1-9.	0.6	4
753	Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis. <i>JACC: CardioOncology</i> , 2021, 3, 619-634.	1.7	49
754	Study of the D-dimer, C-reactive protein, and autoantibodies markers among HBV infected patients in		

#	ARTICLE	IF	CITATIONS
761	âžfè;€ç®¼ç—...ä,çš,,â™™ç»†èfž. Scientia Sinica Vitae, 2021, , .	0.1	0
762	Increased soluble programmed cell death-ligand 1 is associated with acute coronary syndrome. International Journal of Cardiology, 2022, 349, 1-6.	0.8	5
764	CD47â€•and Integrin <i>Î±4</i><i>Î²</i>1â€•Comodifiedâ€•Macrophageâ€•Membraneâ€•Coated Nanoparticles Enable Delivery of Colchicine to Atherosclerotic Plaque. Advanced Healthcare Materials, 2022, 11, e2101788.	3.9	29
765	Factor H-related protein 1 (FHR-1) is associated with atherosclerotic cardiovascular disease. Scientific Reports, 2021, 11, 22511.	1.6	11
766	Immune cell subsets as a marker of development of heart failure: The application of bioinformatics tools. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 849-851.	0.2	0
767	Increased serum C1q/TNF-related protein 4 concentration in patients with acute coronary syndrome. Clinica Chimica Acta, 2022, 524, 187-191.	0.5	4
768	Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials. Journal of Clinical Medicine, 2021, 10, 5366.	1.0	4
769	Advances in Radiopharmaceutical Sciences for Vascular Inflammation Imaging: Focus on Clinical Applications. Molecules, 2021, 26, 7111.	1.7	2
770	Neutrophil-Derived Protein S100A8/A9 Alters the Platelet Proteome in Acute Myocardial Infarction and Is Associated With Changes in Platelet Reactivity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 49-62.	1.1	31
771	Comparative Risk of Incident Coronary Heart Disease Across Chronic Inflammatory Diseases. Frontiers in Cardiovascular Medicine, 2021, 8, 757738.	1.1	3
772	Combined impact of residual inflammatory risk and chronic kidney disease on long-term clinical outcomes in patients undergoing percutaneous coronary intervention. Journal of Cardiology, 2021, , .	0.8	1
773	Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication. JACC: Cardiovascular Imaging, 2022, 15, 460-471.	2.3	37
774	Emerging Anti-Atherosclerotic Therapies. International Journal of Molecular Sciences, 2021, 22, 12109.	1.8	10
775	Nanoparticle theranostics in cardiovascular inflammation. Seminars in Immunology, 2021, 56, 101536.	2.7	13
776	COVID-lateral damage: cardiovascular manifestations of SARS-CoV-2 infection. Translational Research, 2022, 241, 25-40.	2.2	5
777	Clinical significance of colchicine in pharmacotherapy of cardiovascular pathology in patients with hyperuricemia in rheumatic diseases. Meditsinskiy Sovet, 2021, , 188-199.	0.1	0
778	Psycho-cardiology therapeutic effects of Shuangxinfang in rats with depression-behavior post acute myocardial infarction: Focus on protein S100A9 from proteomics. Biomedicine and Pharmacotherapy, 2021, 144, 112303.	2.5	7
779	Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. Future Microbiology, 2021, 16, 1415-1451.	1.0	12

#	ARTICLE	IF	CITATIONS
780	Microvascular Inflammation and Cardiovascular Prevention: The Role of Microcirculation as Earlier Determinant of Cardiovascular Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 41-48.	1.0	8
781	Impaired Redox Homeostasis and Cardiovascular Aging. <i>Healthy Ageing and Longevity</i> , 2022, , 65-86.	0.2	0
782	Statins and Inflammation. <i>Current Atherosclerosis Reports</i> , 2021, 23, 80.	2.0	34
783	Clinical relevance of NETs formation in the development of atherogenic cardiovascular diseases. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2021, 32, 672-678.	0.1	0
784	Endothelial Shear Stress and Atherosclerosis: From Mechanisms to Therapeutics. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
785	Epicardial and periaortic fat characteristics in ischemic stroke: Relationship with stroke etiology and calcification burden. <i>European Journal of Radiology</i> , 2022, 146, 110102.	1.2	0
786	Triiodothyronine (T3), inflammation and mortality risk in patients with acute myocardial infarction. <i>European Thyroid Journal</i> , 2022, 11, .	1.2	3
787	Targeting the NLRP3 inflammasome in cardiovascular diseases. , 2022, 236, 108053.		71
788	SekundÄrprÄvention: Colchicin erneut geprÄft. , 0, , .		0
789	Anti-inflammatory and Immunomodulatory Therapies in Atherosclerosis. <i>Handbook of Experimental Pharmacology</i> , 2021, , 359-404.	0.9	3
790	Sterile Inflammation as a Novel Therapeutic Target to Heart Failure. <i>Yamaguchi Medical Journal</i> , 2021, 70, 65-69.	0.1	0
791	Perivascular adipose tissue in the pathogenesis of cardiovascular disease. <i>Russian Journal of Cardiology</i> , 2021, 26, 4567.	0.4	1
792	COVID-19 Infection and Myocardial Infarction Pathophysiology and Therapy. <i>EMJ Cardiology</i> , 0, , 98-107.	0.0	1
793	A Meta-Analysis Evaluating the Colchicine Therapy in Patients With Coronary Artery Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 740896.	1.1	4
794	Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 804.	1.8	7
795	Anti-inflammatory effects of colchicine on coronary artery disease. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2022, 4, 7-12.	0.0	0
796	Anti-inflammatory strategies for atherosclerotic artery disease. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 661-672.	1.0	4
797	Immunotherapeutic Strategies in Cancer and Atherosclerosisâ€”Two Sides of the Same Coin. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 812702.	1.1	2

#	ARTICLE	IF	CITATIONS
798	Addressing dyslipidemic risk beyond LDL-cholesterol. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	51
799	A pharmacokinetic and pharmacodynamic evaluation of colchicine sustained-release pellets for preventing gout. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 67, 103051.	1.4	3
801	Colchicine for Secondary Prevention of Coronary Artery Disease: A Meta-Analysis of Randomised Controlled Trials. <i>Heart Lung and Circulation</i> , 2022, 31, 685-695.	0.2	3
802	Therapeutic role of immunomodulators during the COVID-19 pandemic – a narrative review. <i>Postgraduate Medicine</i> , 2022, 134, 160-179.	0.9	9
804	Immune modulatory effects of progesterone on oxLDL-induced trained immunity in monocytes. <i>Journal of Leukocyte Biology</i> , 2022, 112, 279-288.	1.5	14
805	Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial. <i>American Heart Journal</i> , 2022, 247, 33-41.	1.2	8
807	Susceptibility to infections and adaptive immunity in adults with heart failure. <i>ESC Heart Failure</i> , 2022, 9, 1195-1205.	1.4	3
808	Colchicine for symptomatic coronary artery disease after percutaneous coronary intervention. <i>Open Heart</i> , 2022, 9, e001887.	0.9	4
809	Additive Effects of Genetic Interleukin-6 Signaling Downregulation and Low-Density Lipoprotein Cholesterol Lowering on Cardiovascular Disease: A 2 ^A –2 Factorial Mendelian Randomization Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, e023277.	1.6	19
810	Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?. <i>Nature Reviews Cardiology</i> , 2022, 19, 522-542.	6.1	125
811	Immune Mechanisms of Plaque Instability. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 797046.	1.1	14
812	Pharmacological inhibition of IRAK1 and IRAK4 prevents endothelial inflammation and atherosclerosis in ApoE ^{-/-} mice. <i>Pharmacological Research</i> , 2022, 175, 106043.	3.1	8
813	Immunity, Vascular Aging and Stroke. <i>Current Medicinal Chemistry</i> , 2022, 29, 5510-5521.	1.2	7
814	Apolipoprotein (a)/Lipoprotein(a)-Induced Oxidative-Inflammatory $\hat{\pm}$ 7-nAChR/p38 MAPK/IL-6/RhoA-GTP Signaling Axis and M1 Macrophage Polarization Modulate Inflammation-Associated Development of Coronary Artery Spasm. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-26.	1.9	11
815	Genetic Predisposition and Inflammatory Inhibitors in COVID-19: Where Do We Stand?. <i>Biomedicines</i> , 2022, 10, 242.	1.4	14
816	Colchicine: protection of the brain beyond the heart?. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 101-103.	1.3	1
817	Colchicine use and the risk of CKD progression: a multicentre nested case-control study. <i>Rheumatology</i> , 2022, 61, 4314-4323.	0.9	3
818	Inflammation Resolution: Implications for Atherosclerosis. <i>Circulation Research</i> , 2022, 130, 130-148.	2.0	49

#	ARTICLE	IF	CITATIONS
819	Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2173-2190.	2.8	42
820	Effects of colchicine on lipolysis and adipose tissue inflammation in adults with obesity and metabolic syndrome. <i>Obesity</i> , 2022, 30, 358-368.	1.5	3
821	Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease. <i>Hypertension Research</i> , 2022, 45, 635-640.	1.5	32
822	Vulnerable Plaque in Patients with Acute Coronary Syndrome: Identification, Importance, and Management. <i>US Cardiology Review</i> , 0, 16, .	0.5	4
823	Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. <i>American Journal of Cardiology</i> , 2022, 168, 47-54.	0.7	4
824	Cost-effectiveness of Canakinumab from a Canadian perspective for recurrent cardiovascular events. <i>CJC Open</i> , 2022, , .	0.7	2
825	Association between C-Reactive Protein Velocity and Left Ventricular Function in Patients with ST-Elevated Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2022, 11, 401.	1.0	10
826	Immune System and Microvascular Remodeling in Humans. <i>Hypertension</i> , 2022, 79, 691-705.	1.3	30
827	Coronary Computed Tomography Angiographic Predictors of Non-culprit Territory Unrecognized Myocardial Infarction Assessed by Cardiac Magnetic Resonance in Non-ST-elevation Acute Coronary Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 825523.	1.1	4
828	OUP accepted manuscript. <i>European Heart Journal</i> , 2022, , .	1.0	1
829	Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management. , 2022, 1, .		22
830	Synergistic Effects of Inflammation and Atherogenic Dyslipidemia on Subclinical Carotid Atherosclerosis Assessed by Ultrasound in Patients with Familial Hypercholesterolemia and Their Family Members. <i>Biomedicines</i> , 2022, 10, 367.	1.4	1
831	Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics. , 2022, 235, 108152.		43
832	Colchicine Against SARS-CoV-2 Infection: What is the Evidence?. <i>Rheumatology and Therapy</i> , 2022, 9, 379-389.	1.1	12
833	Inflammation as a Mechanism and Therapeutic Target in Peripheral Artery Disease. <i>Canadian Journal of Cardiology</i> , 2022, 38, 588-600.	0.8	7
834	Relationship between intracoronary thrombus burden and systemic immune-inflammation index in patients with ST-segment elevation myocardial infarction. <i>Acta Cardiologica</i> , 2023, 78, 72-79.	0.3	10
835	How Single-Cell Technologies Have Provided New Insights Into Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 243-252.	1.1	16
836	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 768-779.	0.5	128

#	ARTICLE	IF	CITATIONS
837	Evaluation of low-dose colchicine in patients with cardiopulmonary bypass: study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e050577.	0.8	6
838	Inflammation and the Link to Vascular Brain Health: Timing Is Brain. <i>Stroke</i> , 2022, 53, 427-436.	1.0	17
839	The effect of trehalose administration on vascular inflammation in patients with coronary artery disease. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112632.	2.5	5
840	Impact of Systemic Inflammatory Response Syndrome on Clinical, Echocardiographic, and Computed Tomographic Outcomes Among Patients Undergoing Transcatheter Aortic Valve Implantation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 746774.	1.1	0
841	Colchicine may become a new cornerstone therapy for coronary artery disease: a meta-analysis of randomized controlled trials. <i>Clinical Rheumatology</i> , 2022, 41, 1873-1887.	1.0	6
842	Clonal hematopoiesis in cardiovascular disease and therapeutic implications. , 2022, 1, 116-124.		32
843	Comment on "Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials". <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3000-3001.	1.1	0
844	Resolution-promoting autacoids demonstrate promising cardioprotective effects against heart diseases. <i>Molecular Biology Reports</i> , 2022, 49, 5179-5197.	1.0	9
845	Relation Between Plasma Proteomics Analysis and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 731325.	1.1	7
846	Gout Is Associated With Worse Post-PCI Long-Term Outcomes. <i>Cardiovascular Revascularization Medicine</i> , 2022, 41, 166-169.	0.3	1
847	Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment. <i>Lancet Neurology</i> , The, 2022, 21, 355-368.	4.9	89
848	Role of Extracellular Vesicles in the Pathogenesis of Vascular Damage. <i>Hypertension</i> , 2022, 79, 863-873.	1.3	27
849	Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications. <i>Journal of the American College of Cardiology</i> , 2022, 79, 577-593.	1.2	34
850	Anti-inflammatory Strategies in Atherosclerosis. <i>Hamostaseologie</i> , 2021, 41, 433-442.	0.9	11
851	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2141328.	2.8	30
852	Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. <i>EBioMedicine</i> , 2021, 74, 103725.	2.7	16
854	Inflammation in Coronary Microvascular Dysfunction. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13471.	1.8	42
855	Atherosclerosis: Pathogenesis and Key Cellular Processes, Current and Emerging Therapies, Key Challenges, and Future Research Directions. <i>Methods in Molecular Biology</i> , 2022, 2419, 3-19.	0.4	9

#	ARTICLE	IF	CITATIONS
856	Key Roles of Inflammation in Atherosclerosis: Mediators Involved in Orchestrating the Inflammatory Response and Its Resolution in the Disease Along with Therapeutic Avenues Targeting Inflammation. <i>Methods in Molecular Biology</i> , 2022, 2419, 21-37.	0.4	6
857	The Role of Tumor Necrosis Factor Associated Factors (TRAFs) in Vascular Inflammation and Atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 826630.	1.1	7
858	New Insights in Prevention and Treatment of Cardiovascular Disease. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2475.	1.2	1
859	Non-invasive Multimodality Imaging of Coronary Vulnerable Patient. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 836473.	1.1	5
860	Acute-Phase Inflammatory Reaction Predicts CMR Myocardial Scar Pattern and 2-Year Mortality in STEMI Patients Undergoing Primary PCI. <i>Journal of Clinical Medicine</i> , 2022, 11, 1222.	1.0	2
861	Myocardial ischemia-reperfusion injury and the influence of inflammation. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 357-366.	2.3	70
862	Greenspace, Inflammation, Cardiovascular Health, and Cancer: A Review and Conceptual Framework for Greenspace in Cardio-Oncology Research. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2426.	1.2	16
863	Immuno-Modulation to Treat Common Cardiovascular Diseases. <i>Journal of the American College of Cardiology</i> , 2022, 79, 648-650.	1.2	0
864	Resolving inflammatory links between myocardial infarction and vascular dementia. <i>Seminars in Immunology</i> , 2022, 59, 101600.	2.7	6
865	Prevalence and real-world management of NSTEMI with multivessel disease. <i>Cardiovascular Diagnosis and Therapy</i> , 2022, 12, 1-11.	0.7	9
866	The Intriguing Role of TLR Accessory Molecules in Cardiovascular Health and Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 820962.	1.1	17
867	New-Onset Atrial Fibrillation Is a Risk Factor of Ischemic Stroke in Chronic Obstructive Pulmonary Disease. <i>Healthcare (Switzerland)</i> , 2022, 10, 381.	1.0	3
868	Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2. <i>Circulation</i> , 2022, 145, 626-628.	1.6	9
869	Pericardial Involvement in ST-Segment Elevation Myocardial Infarction as Detected by Cardiac MRI. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 752626.	1.1	1
870	P2X4 deficiency reduces atherosclerosis and plaque inflammation in mice. <i>Scientific Reports</i> , 2022, 12, 2801.	1.6	6
871	Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review. <i>Biology</i> , 2022, 11, 355.	1.3	32
872	Uncoupling the Vicious Cycle of Mechanical Stress and Inflammation in Calcific Aortic Valve Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 783543.	1.1	18
873	Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS). <i>Journal of Clinical Medicine</i> , 2022, 11, 1762.	1.0	2

#	ARTICLE	IF	CITATIONS
874	P2Y12-dependent activation of hematopoietic stem and progenitor cells promotes emergency hematopoiesis after myocardial infarction. <i>Basic Research in Cardiology</i> , 2022, 117, 16.	2.5	5
875	Mosaic theory revised: inflammation and salt play central roles in arterial hypertension. , 2022, 19, 561-576.		21
876	Atherosclerotic cardiovascular events associated with immune checkpoint inhibitors in cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 659-664.	0.6	5
877	Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities. <i>Journal of Clinical Medicine</i> , 2022, 11, 1361.	1.0	14
878	Platelets, Thromboinflammation and Neurovascular Disease. <i>Frontiers in Immunology</i> , 2022, 13, 843404.	2.2	8
879	Left Ventricular Thrombus Following Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1010-1022.	1.2	53
880	Safety and efficacy of anti-inflammatory therapy in patients with coronary artery disease: a systematic review and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 84.	0.7	8
881	Signaling pathways and targeted therapy for myocardial infarction. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 78.	7.1	175
882	Immunometabolic mechanisms of heart failure with preserved ejection fraction. , 2022, 1, 211-222.		27
883	Elevated Serum Uric Acid and Cardiovascular Disease: A Review and Potential Therapeutic Interventions. <i>Cureus</i> , 2022, 14, e23582.	0.2	5
884	Inflammation influences thrombus burden in STEMI?. <i>Acta Cardiologica</i> , 2022, , 1-1.	0.3	0
885	Targeting the CCL2â€“CCR2 axis for atheroprotection. <i>European Heart Journal</i> , 2022, 43, 1799-1808.	1.0	60
886	Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1308-1321.	2.3	137
887	The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-erythrocytic therapies in atherosclerosis. , 2022, 1, 253-262.		22
888	Inflammatory Links Between Hypertriglyceridemia and Atherogenesis. <i>Current Atherosclerosis Reports</i> , 2022, 24, 297-306.	2.0	15
889	Double-blind, placebo-controlled evaluation of bioresorbable liposomal alendronate in diabetic patients undergoing PCI: The BLADE-PCI trial. <i>American Heart Journal</i> , 2022, 249, 45-56.	1.2	1
890	High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort. <i>Cardiovascular Diabetology</i> , 2022, 21, 46.	2.7	27
891	A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCEâ€“IT Study. <i>Journal of the American Heart Association</i> , 2022, 11, e024176.	1.6	5

#	ARTICLE	IF	CITATIONS
892	Evidence of an anti-inflammatory effect of statins in people living with HIV. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 3069-3071.	1.4	0
893	Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1443-1453.	1.8	3
894	Debris collected in-situ from spontaneously ruptured atherosclerotic plaque invariably contains large cholesterol crystals and evidence of activation of innate inflammation: Insights from non-obstructive general angioscopy. <i>Atherosclerosis</i> , 2022, 352, 96-102.	0.4	12
895	Macrophage Polarization in the Perivascular Fat Was Associated With Coronary Atherosclerosis. <i>Journal of the American Heart Association</i> , 2022, 11, e023274.	1.6	13
896	Colchicineâ€™regeneration of an old drug. <i>Irish Journal of Medical Science</i> , 2023, 192, 115-123.	0.8	5
897	Thiols and disulfide levels are correlated with TIMI thrombus grade in non-ST elevation myocardial infarction patients. <i>Biomarkers in Medicine</i> , 2022, 16, 233-240.	0.6	1
898	Is Colchicine a New Game-Changer in Patients With Acute Coronary Syndrome?. <i>Cureus</i> , 2022, 14, e22874.	0.2	0
899	Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus. <i>Seminars in Immunopathology</i> , 2022, 44, 309-324.	2.8	18
900	Cardio-Rheumatology. <i>Medical Clinics of North America</i> , 2022, 106, 349-363.	1.1	3
901	Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 443-460.	2.5	5
902	Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 841545.	1.1	17
903	Ceramides and phospholipids in plasma extracellular vesicles are associated with high risk of major cardiovascular events after carotid endarterectomy. <i>Scientific Reports</i> , 2022, 12, 5521.	1.6	8
904	Crosstalk Between Macrophages and Vascular Smooth Muscle Cells in Atherosclerotic Plaque Stability. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 372-380.	1.1	30
905	Colchicine for Patients With Coronary Artery Disease: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, 420-430.	0.8	2
906	Intravascular imaging assessment of pharmacotherapies targeting atherosclerosis: advantages and limitations in predicting their prognostic implications. <i>Cardiovascular Research</i> , 2023, 119, 121-135.	1.8	7
907	Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction. <i>EBioMedicine</i> , 2022, 78, 103964.	2.7	30
908	Acute coronary syndromes. <i>Lancet, The</i> , 2022, 399, 1347-1358.	6.3	122
909	Regional analysis of inflammation and contractile function in reperfused acute myocardial infarction by in vivo ¹⁹ F cardiovascular magnetic resonance in pigs. <i>Basic Research in Cardiology</i> , 2022, 117, 21.	2.5	19

#	ARTICLE	IF	CITATIONS
910	2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 101161ATVBAHA122317049.	1.1	5
911	Potential role for pentoxifylline as an anti-inflammatory drug for patients with acute coronary syndrome. <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 378.	0.8	3
912	Pharmacological Targeting of the CCL2/CCR2 Axis for Atheroprotection: A Meta-Analysis of Preclinical Studies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 101161ATVBAHA122317492.	1.1	8
913	Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis. <i>Pharmacological Research</i> , 2022, 178, 106157.	3.1	14
914	Acute exposure to phthalates during recovery from a myocardial infarction induces greater inflammasome activation in male C57bl/6N mice. <i>Toxicology and Applied Pharmacology</i> , 2022, 440, 115954.	1.3	4
915	Emerging evidence for the use of colchicine for secondary prevention of coronary heart disease. <i>Medical Journal of Australia</i> , 2022, , .	0.8	1
916	A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. <i>Science Translational Medicine</i> , 2022, 14, eabj9625.	5.8	31
917	Association of residual inflammatory risk with stroke recurrence in patients with acute ischaemic stroke or transient ischaemic attack. <i>European Journal of Neurology</i> , 2022, 29, 2258-2268.	1.7	3
918	Inflammation and resolution signaling in cardiac repair and heart failure. <i>EBioMedicine</i> , 2022, 79, 103992.	2.7	70
919	Nrf2 attenuates the innate immune response after experimental myocardial infarction. <i>Biochemical and Biophysical Research Communications</i> , 2022, 606, 10-16.	1.0	4
920	Managing Cardiovascular Risk in Patients with Rheumatic Disease. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 429-444.	0.8	4
921	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. <i>American Journal of Preventive Cardiology</i> , 2022, 10, 100335.	1.3	58
922	The role of the mineralocorticoid receptor in immune cells in cardiovascular disease. <i>British Journal of Pharmacology</i> , 2022, 179, 3135-3151.	2.7	16
923	Neopterin and kynurenic acid as predictors of stroke recurrence and mortality: a multicentre prospective cohort study on biomarkers of inflammation measured three months after ischemic stroke. <i>BMC Neurology</i> , 2021, 21, 476.	0.8	1
924	Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 3391-3404.	0.4	3
925	Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. <i>Nature Reviews Rheumatology</i> , 2022, 18, 97-111.	3.5	45
926	The effect of therapy on subclinical atherosclerosis of the carotid arteries in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis (pilot study). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 708-714.	0.2	1
927	Effect of colchicine, methotrexate, and hydroxychloroquine therapy on cardiovascular outcomes in patients with calcium pyrophosphate crystal deposition disease. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 76-83.	0.1	1

#	ARTICLE	IF	CITATIONS
928	Circulating Interleukin-6 Levels and Incident Ischemic Stroke. <i>Neurology</i> , 2022, 98, .	1.5	29
929	A Review of the Rational and Current Evidence on Colchicine for COVID-19. <i>Current Pharmaceutical Design</i> , 2022, 28, 3194-3201.	0.9	2
930	Hyperuricemia, Gout, and the Brain—An Update. <i>Current Rheumatology Reports</i> , 2021, 23, 82.	2.1	17
931	Comprehensive Assessment of High-Risk Plaques by Dual-Modal Imaging Catheter in Coronary Artery. <i>JACC Basic To Translational Science</i> , 2021, 6, 948-960.	1.9	8
932	Network Pharmacology-Based Investigation and Experimental Exploration of the Antiapoptotic Mechanism of Colchicine on Myocardial Ischemia Reperfusion Injury. <i>Frontiers in Pharmacology</i> , 2021, 12, 804030.	1.6	10
933	Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 583.	0.7	19
935	Recent Advances on the Role and Therapeutic Potential of Regulatory T Cells in Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 5907.	1.0	5
936	oxLDL-Induced Trained Immunity Is Dependent on Mitochondrial Metabolic Reprogramming. <i>Immunometabolism</i> , 2021, 3, e210025.	0.7	20
937	Radionuclide-based imaging of the aortic wall. , 2022, , 91-109.		0
938	Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons. <i>Journal of Clinical Medicine</i> , 2022, 11, 1771.	1.0	12
939	The cardiovascular effects and safety of colchicine. <i>Pharmacy & Pharmacology International Journal</i> , 2022, 10, 40-45.	0.1	0
940	The Role of the Association Between Serum C-Reactive Protein Levels and Coronary Plaque Macrophage Accumulation in Predicting Clinical Events — Results from the CLIMA Registry. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 1377-1384.	1.1	3
941	Residual Inflammatory Risk After Percutaneous Coronary Intervention. <i>JACC Asia</i> , 2022, , .	0.5	0
942	Macrophage Dysfunction in Autoimmune Rheumatic Diseases and Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4513.	1.8	9
943	Intravital Imaging Reveals the Ameliorating Effect of Colchicine in a Photothrombotic Stroke Model via Inhibition of Neutrophil Recruitment. <i>Translational Stroke Research</i> , 2022, , .	2.3	0
944	Effect of Lipoprotein(a) on Stroke Recurrence Attenuates at Low LDL-C (Low-Density Lipoprotein) and Inflammation Levels. <i>Stroke</i> , 2022, 53, 2504-2511.	1.0	14
945	The Spectrum of B Cell Functions in Atherosclerotic Cardiovascular Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 864602.	1.1	9
946	Effect of Treatment with Colchicine after Acute Coronary Syndrome on Major Cardiovascular Events: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Cardiovascular Therapeutics</i> , 2022, 2022, 1-12.	1.1	8

#	ARTICLE	IF	CITATIONS
947	Association of Plaque Inflammation With Stroke Recurrence in Patients With Unproven Benefit From Carotid Revascularization. <i>Neurology</i> , 2022, 99, .	1.5	2
948	Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. <i>Revista Espanola De Cardiologia</i> , 2022, 75, 429.e1-429.e104.	0.6	27
949	Metabolomics of Arterial Stiffness. <i>Metabolites</i> , 2022, 12, 370.	1.3	10
950	<scp>Timeâ€Varying</scp> Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk. <i>ACR Open Rheumatology</i> , 2022, 4, 587-595.	0.9	8
951	Are we any WISER yet? Progress and contemporary need for smart trials to include women in coronary artery disease trials. <i>Contemporary Clinical Trials</i> , 2022, 117, 106762.	0.8	6
952	Differences of inflammatory cytokine profile in patients with vulnerable plaque: A coronary CTA study. <i>Atherosclerosis</i> , 2022, 350, 25-32.	0.4	2
953	Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1435-1442.	1.8	3
954	Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention. <i>JACC Asia</i> , 2022, 2, 323-337.	0.5	5
955	Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke. <i>Circulation Research</i> , 2022, 130, 1167-1186.	2.0	74
971	Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 131.	7.1	190
972	Proteomic Characterization of Atherosclerotic Lesions In Situ Using Percutaneous Coronary Intervention Angioplasty Balloonsâ€”Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 857-864.	1.1	4
973	Colchicine in Cardiovascular Disease: In-Depth Review.. <i>Circulation</i> , 2022, 145, 61-78.	1.6	37
974	Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003911.	3.9	21
976	SYNTAXES, biomarkers and survival in complex coronary artery disease: the intervention of secondary prevention. <i>EuroIntervention</i> , 2022, 17, 1460-1462.	1.4	1
977	Cardiovascular prevention trials: cross-examining colchicine. <i>Canadian Family Physician</i> , 2022, 68, 35-35.	0.1	0
979	Exosomes in atherosclerosis: Convergence on macrophages. <i>International Journal of Biological Sciences</i> , 2022, 18, 3266-3281.	2.6	18
980	Role of inflammatory markers in the diagnosis of vascular contributions to cognitive impairment and dementia: a systematic review and meta-analysis. <i>GeroScience</i> , 2022, 44, 1373-1392.	2.1	36
981	Early Detection of Inflammation-Prone STEMI Patients Using the CRP Troponin Test (CTT). <i>Journal of Clinical Medicine</i> , 2022, 11, 2453.	1.0	5

#	ARTICLE	IF	CITATIONS
982	Macrophages in Atheromatous Plaque Developmental Stages. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 865367.	1.1	4
983	2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2022, 21, 3235.	0.4	37
984	Undertreatment or Overtreatment With Statins: Where Are We?. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 808712.	1.1	9
985	Association of colchicine use for acute gout with clinical outcomes in acute decompensated heart failure. <i>Clinical Cardiology</i> , 2022, 45, 733-741.	0.7	9
986	Pharmacogenetic Perspective for Optimal Gout Management. <i>Future Pharmacology</i> , 2022, 2, 135-152.	0.6	8
988	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. <i>American Heart Journal</i> , 2022, 251, 13-24.	1.2	6
989	Arterial Stiffness and Adult Onset Vasculitis: A Systematic Review. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	6
991	The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 183-190.	1.0	4
992	Systemic Inflammation Is Associated With Future Risk of Fatal Infection: An Observational Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 226, 554-562.	1.9	5
993	Immune and Inflammatory Networks in Myocardial Infarction: Current Research and Its Potential Implications for the Clinic. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5214.	1.8	18
994	Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach. <i>European Journal of Pharmacology</i> , 2022, 925, 174998.	1.7	5
995	Innate immune signaling and immunothrombosis: New insights and therapeutic opportunities. <i>European Journal of Immunology</i> , 2022, 52, 1024-1034.	1.6	12
996	The Management of Cardiovascular Disease Risk in Patients with Rheumatoid Arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2022, , .	0.9	1
997	Editorial: Targeting Dysregulated Inflammation to Treat Cardiovascular Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	0
998	The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice. <i>Acta Cardiologica</i> , 2023, 78, 552-564.	0.3	2
999	Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?. <i>Basic Research in Cardiology</i> , 2022, 117, 28.	2.5	9
1000	Arterial myeloperoxidase in the detection and treatment of vulnerable atherosclerotic plaque: a new dawn for an old light. <i>Cardiovascular Research</i> , 2023, 119, 112-120.	1.8	7
1001	Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophagesâ€™ transition into a pro-inflammatory state. <i>Cardiovascular Research</i> , 2023, 119, 1146-1160.	1.8	18

#	ARTICLE	IF	CITATIONS
1002	Cardiovascular Diseases and Periodontitis. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 261-280.	0.8	13
1004	Inflammatory Diseases and Risk of Atherosclerotic Cardiovascular Disease: A New Focus on Prevention. <i>Contemporary Cardiology</i> , 2022, , 247-270.	0.0	3
1005	Targeting Microtubules for the Treatment of Heart Disease. <i>Circulation Research</i> , 2022, 130, 1723-1741.	2.0	5
1006	The Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 819-830.	1.1	10
1007	Could targeting the macrophage urokinase-type plasminogen activator receptor be a bullseye for PET imaging of atherosclerotic plaque inflammation?. <i>Atherosclerosis</i> , 2022, , .	0.4	0
1008	The effect of cold exposure on circulating transcript levels of immune genes in Dutch South Asian and Dutch Europid men. <i>Journal of Thermal Biology</i> , 2022, 107, 103259.	1.1	3
1009	Oxidative Stress in Men with Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: Mechanisms and Management of Reproductive Dysfunction. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 237-256.	0.8	3
1010	Impact of Neutrophil Extracellular Traps on Thrombosis Formation: New Findings and Future Perspective. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	1.8	19
1011	Hearts on Fire: The Role of Inflammation in the Pathogenesis of Atherosclerotic Cardiovascular Disease and How We Can Tend to the Flames. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1553-1557.	0.8	3
1012	Modulation of Tissue Microenvironment Following Myocardial Infarction. <i>Advanced NanoBiomed Research</i> , 0, , 2200005.	1.7	2
1013	Repurposing drugs to treat cardiovascular disease in the era of precision medicine. <i>Nature Reviews Cardiology</i> , 2022, 19, 751-764.	6.1	29
1014	Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. <i>Atherosclerosis Plus</i> , 2022, 49, 20-27.	0.3	4
1015	Modern Concepts in Cardiovascular Disease: Inflamm-Aging. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	12
1016	Socioeconomic disparity in cardiovascular disease: Possible biological pathways based on a proteomic approach. <i>Atherosclerosis</i> , 2022, 352, 62-68.	0.4	2
1017	Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	10
1018	Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1323-1329.	0.5	7
1020	Extracellular Vesicles as Drivers of Immunoinflammation in Atherothrombosis. <i>Cells</i> , 2022, 11, 1845.	1.8	16
1021	Somatic Mutations and Clonal Hematopoiesis as Drivers of Age-Related Cardiovascular Risk. <i>Current Cardiology Reports</i> , 2022, 24, 1049-1058.	1.3	9

#	ARTICLE	IF	CITATIONS
1022	Kardiorenales Syndrom: Herz- und Niereninsuffizienz gleichzeitig im Fokus. , 0, , .		1
1023	C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study. Cardiovascular Drugs and Therapy, 0, , .	1.3	1
1024	Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial. Scientific Reports, 2022, 12, .	1.6	6
1025	Effect of colchicine on inflammatory markers in patients with coronary artery disease: A meta-analysis of clinical trials. European Journal of Pharmacology, 2022, 927, 175068.	1.7	3
1026	Managing residual inflammatory risk in atherosclerotic cardiovascular disease: another piece of the puzzle?. Cardiology Plus, 2022, 7, 1-2.	0.2	1
1027	Extracellular Inflammasome Particles Are Released After Marathon Running and Induce Proinflammatory Effects in Endothelial Cells. Frontiers in Physiology, 0, 13, .	1.3	3
1028	The Efficacy and Underlying Mechanism of Berberine against Atherosclerosis: a Meta-analysis in Preclinical Animal Studies. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, .	0.8	0
1029	High-Risk Coronary Plaque Features: A Narrative Review. Cardiology and Therapy, 2022, 11, 319-335.	1.1	5
1030	Select drug-drug interactions with colchicine and cardiovascular medications: A review. American Heart Journal, 2022, 252, 42-50.	1.2	6
1031	Animal Models of Atherosclerosisâ€“Supportive Notes and Tricks of the Trade. Circulation Research, 2022, 130, 1869-1887.	2.0	26
1032	Editorial: New Insights Into Oxidative Stress and Inflammation in the Pathophysiology and Treatment of Cardiovascular Diseases. Frontiers in Molecular Biosciences, 0, 9, .	1.6	1
1033	Idiopathic Recurrent Pericarditis: Not Really So Idiopathic?. Journal of the American Heart Association, 2022, 11, .	1.6	2
1034	Colchicine for Coronary Artery Disease: A Review. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
1035	Inflammation, new bone formation and aorta. International Journal of Rheumatic Diseases, 2022, 25, 910-915.	0.9	1
1036	Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD Open, 2022, 8, e001944.	1.8	9
1037	Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know. Current Atherosclerosis Reports, 0, , .	2.0	4
1038	Inflammation, Lymphatics, and Cardiovascular Disease: Amplification by Chronic Kidney Disease. Current Hypertension Reports, 2022, 24, 455-463.	1.5	6
1039	Colchicine and Quality of Life in Patients With Acute Coronary Syndromes: Results From the COPS Randomized Trial. Cardiovascular Revascularization Medicine, 2022, 44, 53-59.	0.3	3

#	ARTICLE	IF	CITATIONS
1040	Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6648.	1.8	3
1041	Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?. , 2022, 237, 108228.		9
1042	Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies. <i>International Journal of Cardiology</i> , 2022, 363, 20-22.	0.8	5
1043	The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events. <i>European Heart Journal Open</i> , 2022, 2, .	0.9	9
1044	Lipoxins reduce obesity-induced adipose tissue inflammation in 3D-cultured human adipocytes and explant cultures. <i>IScience</i> , 2022, 25, 104602.	1.9	4
1045	Vasculome. , 2022, , 441-451.		0
1046	Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study. <i>Journal of Neuroinflammation</i> , 2022, 19, .	3.1	29
1047	Preprocedural Colchicine in Patients With Acute ST-elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Randomized Controlled Trial (PodCAST-PCI). <i>Journal of Cardiovascular Pharmacology</i> , 2022, 80, 592-599.	0.8	7
1048	Role of Inflammation in Cardiac Remodeling After Acute Myocardial Infarction. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	12
1049	Colchicine for the primary prevention of cardiovascular events. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	1
1050	Evaluating the Utility of Colchicine in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 80, 639-647.	0.8	2
1051	Reply to Letter to the editor regarding the article: "Inflammation and ischemic heart disease: The next therapeutic target?" Revista Portuguesa De Cardiologia, 2022, , .	0.2	0
1052	Colchicine Impacts Leukocyte Trafficking in Atherosclerosis and Reduces Vascular Inflammation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
1053	The role of inflammation in percutaneous coronary intervention, from balloon angioplasty to drug eluting stents. <i>Minerva Cardiology and Angiology</i> , 0, , .	0.4	0
1054	Heart Failure in Chronic Infectious and Inflammatory Conditions: Mechanistic Insights from Clinical Heterogeneity. <i>Current Heart Failure Reports</i> , 2022, 19, 267-278.	1.3	2
1055	Optimization and Characterization of a Liposomal Azithromycin Formulation for Alternative Macrophage Activation. <i>Frontiers in Drug Delivery</i> , 0, 2, .	0.4	0
1056	Efficacy and Safety of Colchicine in Prevention of Secondary Cardiovascular Outcomes Among Patients With Coronary Vessel Disease: A Meta-Analysis. <i>Cureus</i> , 2022, , .	0.2	2
1057	Depletion of Foxp3+ regulatory T cells augments CD4+ T cell immune responses in atherosclerosis-prone hypercholesterolemic mice. <i>Heliyon</i> , 2022, 8, e09981.	1.4	2

#	ARTICLE	IF	CITATIONS
1058	Colchicine for cardiovascular medicine: a systematic review and meta-analysis. <i>Future Cardiology</i> , 2022, 18, 647-659.	0.5	9
1059	Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. <i>Expert Review of Cardiovascular Therapy</i> , 0, , 1-13.	0.6	1
1060	The Role of Colchicine in Atherosclerosis: From Bench to Bedside. <i>Pharmaceutics</i> , 2022, 14, 1395.	2.0	6
1061	Colchicine Ameliorates Dilated Cardiomyopathy Via SIRT2-Mediated Suppression of NLRP3 Inflammasome Activation. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	15
1062	Pharmacologic modulation of intracellular Na ⁺ concentration with ranolazine impacts inflammatory response in humans and mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	3
1063	Um Novo Preditor de Risco no Infarto Agudo do Miocrdio. Ainda tem Lugar para Mais Um?. <i>Arquivos Brasileiros De Cardiologia</i> , 2022, 119, 23-24.	0.3	0
1064	The Roles of Neutrophils Linking Periodontitis and Atherosclerotic Cardiovascular Diseases. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	19
1065	Decoding microRNA drivers in atherosclerosis. <i>Bioscience Reports</i> , 2022, 42, .	1.1	11
1066	Mitochondria-targeted esculetin mitigates atherosclerosis in the setting of aging via the modulation of SIRT1-mediated vascular cell senescence and mitochondrial function in Apoe mice. <i>Atherosclerosis</i> , 2022, 356, 28-40.	0.4	19
1067	The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
1068	Colchicine Inhibits NETs and Alleviates Cardiac Remodeling after Acute Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2024, 38, 31-41.	1.3	12
1069	Cardiovascular Disease in Myeloproliferative Neoplasms. <i>JACC: CardioOncology</i> , 2022, 4, 166-182.	1.7	23
1070	Association between gout and cardiovascular outcomes in adults with no history of cardiovascular disease: large data linkage study in New Zealand. , 2022, 1, e000081.		7
1071	Portable air cleaner use and biomarkers of inflammation: A systematic review and meta-analysis. <i>American Heart Journal Plus</i> , 2022, 18, 100182.	0.3	2
1072	Colchicine may decrease cardiovascular events in patients with coronary artery disease. , 2022, 71, .		0
1073	Efficacy of Colchicine in the Treatment of Patients With Coronary Artery Disease: A Mini-Review. <i>Clinical Therapeutics</i> , 2022, 44, 1150-1159.	1.1	3
1074	Treatment strategies of acute myocardial infarction: updates on revascularization, pharmacological therapy, and beyond. <i>Journal of Cardiology</i> , 2023, 81, 168-178.	0.8	17
1075	Major cardiovascular events in patients with severe COPD with and without asthma: a nationwide cohort study. <i>ERJ Open Research</i> , 2022, 8, 00200-2022.	1.1	1

#	ARTICLE	IF	CITATIONS
1076	Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. <i>European Heart Journal</i> , 2022, 43, 4832-4844.	1.0	31
1077	Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
1078	Treatment of periodontitis and C-reactive protein: A systematic review and meta-analysis of randomized clinical trials. <i>Journal of Clinical Periodontology</i> , 2023, 50, 45-60.	2.3	10
1079	Gut immune cells: A novel therapeutical target for cardiovascular disease?. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
1080	Systemic inflammation after stroke: implications for post-stroke comorbidities. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	49
1081	NLRP3-mediated inflammation in cardio-oncology: sterile yet harmful. <i>Translational Research</i> , 2023, 252, 9-20.	2.2	7
1082	Global research trends in atherosclerosis: A bibliometric and visualized study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6
1083	Editorial: Targeting innate and adaptive immunity for improvement of cardiovascular disease. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	0
1084	Neutrophils and Neutrophil Extracellular Traps in Cardiovascular Disease: An Overview and Potential Therapeutic Approaches. <i>Biomedicines</i> , 2022, 10, 1850.	1.4	9
1085	Cardiovascular Events and Gout Flares. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 425.	3.8	2
1086	Inflammation and vascular diseases. <i>Vnitřní Lekarství</i> , 2022, 68, 309-314.	0.1	0
1087	Increased serum S100A12 levels are associated with higher risk of acute heart failure in patients with type 2 diabetes. <i>ESC Heart Failure</i> , 2022, 9, 3909-3919.	1.4	7
1088	Systemic lupus erythematosus and cardiovascular disease. <i>Journal of Internal Medicine</i> , 2023, 293, 48-62.	2.7	17
1089	Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. <i>Cardiovascular Research</i> , 2023, 118, 3536-3555.	1.8	29
1090	Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. <i>Journal of Clinical Lipidology</i> , 2022, , .	0.6	0
1091	Unravelling the role of macrophages in cardiovascular inflammation through imaging: a state-of-the-art review. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, e504-e525.	0.5	5
1092	The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents. <i>International Immunopharmacology</i> , 2022, 111, 109080.	1.7	28
1093	Colchicine: Emerging therapeutic effects on atrial fibrillation by alleviating myocardial fibrosis in a rat model. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113573.	2.5	5

#	ARTICLE	IF	CITATIONS
1094	GlycA, hsCRP differentially associated with MI, ischemic stroke: In the Dallas Heart Study and Multi-Ethnic Study of Atherosclerosis. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100373.	1.3	7
1095	Targeted delivery of platelet membrane modified extracellular vesicles into atherosclerotic plaque to regress atherosclerosis. <i>Chemical Engineering Journal</i> , 2023, 452, 138992.	6.6	6
1096	Colchicine and coronary heart disease risks: A meta-analysis of randomized controlled clinical trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	5
1098	Tackling inflammation in atherosclerosis: Are we there yet and what lies beyond?. <i>Current Opinion in Pharmacology</i> , 2022, 66, 102283.	1.7	12
1099	Association of MMP9 with adverse features of plaque progression and residual inflammatory risk in patients with chronic coronary syndrome (CCS). <i>Vascular Pharmacology</i> , 2022, 146, 107098.	1.0	2
1100	Data-driven clustering approach to identify novel phenotypes using multiple biomarkers in acute ischaemic stroke: A retrospective, multicentre cohort study. <i>EClinicalMedicine</i> , 2022, 53, 101639.	3.2	9
1101	Effect of different doses of colchicine on high sensitivity C-reactive protein in patients with acute minor stroke or transient ischemic attack: A pilot randomized controlled trial. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 178, 106288.	1.9	1
1102	Functions and therapeutic interventions of non-coding RNAs associated with TLR signaling pathway in atherosclerosis. <i>Cellular Signalling</i> , 2022, 100, 110471.	1.7	8
1103	Polypharmacology in Old Drug Rediscovery: Drug Repurposing. , 2022, , 535-592.		2
1104	The Top Five Papers of 2020 for General Internists. <i>Canadian Journal of General Internal Medicine</i> , 2022, 17, 86-93.	0.6	0
1105	Cardiorenal Syndrome. <i>Nephrology Self-assessment Program: NephSAP</i> , 2022, 21, 29-40.	3.0	0
1106	Aortic valve stenosis: drivers of disease progression and drug targets for therapeutic opportunities. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 633-644.	1.5	2
1107	Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	29
1108	Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1802-1814.	1.2	8
1110	Regulated Necrosis in Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 1283-1306.	1.1	23
1111	Research advance and clinical implication of circZNF609 in human diseases. <i>Biotechnology and Biotechnological Equipment</i> , 2022, 36, 668-683.	0.5	0
1112	Examining the potential direct cardiovascular benefit of tumor necrosis factor inhibitor in rheumatoid arthritis: Natural and controlled direct effect analyses. <i>Pharmacoepidemiology and Drug Safety</i> , 2023, 32, 407-415.	0.9	1
1113	Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research. <i>Nature Reviews Cardiology</i> , 2023, 20, 181-196.	6.1	28

#	ARTICLE	IF	CITATIONS
1114	New play for an old actress: A Cinderella in cardiovascular disease. <i>International Journal of Cardiology</i> , 2022, , .	0.8	0
1115	CCL24/CCR3 axis plays a central role in angiotensin II-induced heart failure by stimulating M2 macrophage polarization and fibroblast activation. <i>Cell Biology and Toxicology</i> , 2023, 39, 1413-1431.	2.4	5
1116	A Decade On: The Evolving Renaissance in Intracranial Atherosclerotic Disease. , 2022, 2, .		3
1117	Integrated Transcriptome and Proteome Analysis Reveals that the Antimicrobial Griseofulvin Targets <i>Didymella segeticola</i> beta-Tubulin to Control Tea Leaf Spot. <i>Phytopathology</i> , 0, , .	1.1	1
1118	NLRP3 inflammasome: The rising star in cardiovascular diseases. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	25
1119	How dysregulation of the immune system promotes diabetes mellitus and cardiovascular risk complications. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	11
1120	The Amino Acid Homoarginine Inhibits Atherogenesis by Modulating T-Cell Function. <i>Circulation Research</i> , 2022, 131, 701-712.	2.0	12
1121	The interaction between hyperuricemia and low-density lipoprotein cholesterol increases the risk of 1-year post-discharge all-cause mortality in ST-segment elevation myocardial infarction patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2023, 33, 133-140.	1.1	2
1122	Beyond joint pain, could each gout flare lead to heart attack?. <i>Nature Reviews Rheumatology</i> , 2022, 18, 619-620.	3.5	2
1123	Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1990-1999.	1.1	1
1124	Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
1125	Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. <i>Lancet, The</i> , 2022, 400, 733-743.	6.3	122
1126	Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 762-778.	4.1	51
1127	Association of immune cell subsets with incident heart failure in two population-based cohorts. <i>ESC Heart Failure</i> , 0, , .	1.4	2
1128	Incident gout and risk of first-time acute coronary syndrome: a prospective, population-based, cohort study in Sweden. <i>Arthritis Care and Research</i> , 0, , .	1.5	0
1129	Autoimmune diseases and atherothrombotic risk. <i>Lancet, The</i> , 2022, 400, 708-710.	6.3	0
1130	Myeloid But Not Endothelial Expression of the CB2 Receptor Promotes Atherogenesis in the Context of Elevated Levels of the Endocannabinoid 2-Arachidonoylglycerol. <i>Journal of Cardiovascular Translational Research</i> , 0, , .	1.1	2
1131	Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios Are Associated with Recurrent Ischemic Stroke in Patients with Embolic Stroke of Undetermined Source. <i>Journal of Stroke</i> , 2022, 24, 421-424.	1.4	4

#	ARTICLE	IF	CITATIONS
1132	Building a better NET: Neutrophil extracellular trap targeted therapeutics in the treatment of infectious and inflammatory disorders. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12808.	1.0	8
1134	Evolocumab for prevention of microvascular dysfunction in patients undergoing percutaneous coronary intervention: the randomised, open-label EVOCATION trial. <i>EuroIntervention</i> , 2022, 18, e647-e655.	1.4	7
1135	Sustained release of drug-loaded nanoparticles from injectable hydrogels enables long-term control of macrophage phenotype. <i>Biomaterials Science</i> , 2022, 10, 6951-6967.	2.6	13
1136	Peripheral Arterial Atherogenesis. <i>Contemporary Cardiology</i> , 2022, , 1-48.	0.0	0
1137	Atherosclerosis Imaging. , 2022, , 241-254.		0
1138	Heparanase: A Novel Therapeutic Target for the Treatment of Atherosclerosis. <i>Cells</i> , 2022, 11, 3198.	1.8	10
1139	Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention. <i>Atherosclerosis</i> , 2022, 363, 109-116.	0.4	8
1140	Impact of Obstructive Sleep Apnea Syndrome on Ventricular Remodeling after Acute Myocardial Infarction: A Proof-of-Concept Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 6341.	1.0	1
1141	Drug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
1142	A bibliometric analysis of T cell and atherosclerosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
1143	Interleukin-1 in Coronary Artery Disease. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 2368-2389.	1.0	17
1144	Research Progress on the Role of Pyroptosis in Myocardial Ischemia-Reperfusion Injury. <i>Cells</i> , 2022, 11, 3271.	1.8	15
1145	âœVascular inflammation and cardiovascular disease: review about the role of PET imagingâœ. <i>International Journal of Cardiovascular Imaging</i> , 2023, 39, 433-440.	0.7	6
1146	Construction of an immune-related signature for predicting the ischemic events in patients undergoing carotid endarterectomy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
1147	Magnitude of Low-density Lipoprotein Reduction and Impact on Major Cardiovascular Outcomes. <i>Journal of Cardiovascular Pharmacology</i> , 2023, 81, 15-17.	0.8	2
1148	The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose ColchicineÂ2 (LoDoCo2) Trial. <i>Clinical Drug Investigation</i> , 2022, 42, 977-985.	1.1	9
1149	Mechanosensitive Stem-Cell Genes and Klotho in Atherosclerotic Aortas: Regulating Spatially Deranged Expression Patterns Using Colchicine Regimens. <i>Journal of Clinical Medicine</i> , 2022, 11, 6465.	1.0	3
1150	Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy. <i>Heart Failure Reviews</i> , 0, , .	1.7	9

#	ARTICLE	IF	CITATIONS
1151	Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12054.	1.8	9
1152	Formulation and Evaluation of a Drug-in-Adhesive Patch for Transdermal Delivery of Colchicine. <i>Pharmaceutics</i> , 2022, 14, 2245.	2.0	5
1153	Serum high mobility group box-1 levels associated with cardiovascular events after lower extremity revascularization: a prospective study of a diabetic population. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	4
1154	The relationships between cholesterol crystals, NLRP3 inflammasome, and coronary atherosclerotic plaque vulnerability in acute coronary syndrome: An optical coherence tomography study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
1155	Association between tissue human neutrophil peptide 1 α levels and cardiovascular phenotype: a prospective, longitudinal cohort study. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211270.	0.4	0
1156	Colchicine pre-treatment and post-treatment does not worsen bleeding or functional outcome after collagenase-induced intracerebral hemorrhage. <i>PLoS ONE</i> , 2022, 17, e0276405.	1.1	1
1157	The Role of Inflammation in Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12906.	1.8	86
1158	Inhibition of the Mechanistic Target of Rapamycin in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1815-1817.	1.2	0
1159	Common NLRP3 inflammasome inhibitors and Covid-19: Divide and conquer. <i>Scientific African</i> , 2022, 18, e01407.	0.7	13
1160	Long-term Management of Patients with Myocardial Infarction: An Updated Review. , 0, Publish Ahead of Print, .		1
1161	The Effect of Colchicine in Acute Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2024, 38, 199-199.	1.3	0
1162	Clinical utility of coronary artery computed tomography angiography- What we know and What's new?. <i>Progress in Cardiovascular Diseases</i> , 2022, 75, 12-20.	1.6	5
1163	The AIM2 inflammasome: A novel biomarker and target in cardiovascular disease. <i>Pharmacological Research</i> , 2022, 186, 106533.	3.1	15
1164	PCSK9 pathway-noncoding RNAs crosstalk: Emerging opportunities for novel therapeutic approaches in inflammatory atherosclerosis. <i>International Immunopharmacology</i> , 2022, 113, 109318.	1.7	4
1165	Alkaloids and COVID-19. , 2023, , 125-141.		0
1166	Efeitos Anti-inflamat \acute{o} rios e Cardioprotetores do HDL-C: Associa \tilde{c} o com Autoanticorpos contra LDL Oxidada?. <i>Arquivos Brasileiros De Cardiologia</i> , 2022, 119, 722-723.	0.3	0
1168	Immuno-cardio-oncology: Killing two birds with one stone?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1169	Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100432.	1.3	10

#	ARTICLE	IF	CITATIONS
1170	Trajectories and determinants of left ventricular ejection fraction after the first myocardial infarction in the current era of primary coronary interventions. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
1171	Earlier treatment in adults with high lifetime risk of cardiovascular diseases: What prevention trials are feasible and could change clinical practice? Report of a National Heart, Lung, and Blood Institute (NHLBI) Workshop. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100430.	1.3	8
1172	Non-Coding RNAs in Regulating Plaque Progression and Remodeling of Extracellular Matrix in Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13731.	1.8	6
1173	Therapeutic role of colchicine in reducing cardiovascular risk associated with inflammation. <i>Endocrinología y Nutrición (English Ed)</i> , 2022, , .	0.1	0
1174	Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, , .	1.2	3
1175	Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. <i>EClinicalMedicine</i> , 2023, 55, 101737.	3.2	8
1176	Prognostic impacts of Lipoxin A4 in patients with acute myocardial infarction: A prospective cohort study. <i>Pharmacological Research</i> , 2023, 187, 106618.	3.1	1
1177	Systematic review of colchicine neuromyopathy: Risk factors, duration and resolution. <i>Seminars in Arthritis and Rheumatism</i> , 2023, 58, 152150.	1.6	2
1178	Revisiting secondary prevention in coronary heart disease. <i>Indian Heart Journal</i> , 2022, 74, 431-440.	0.2	7
1179	Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio. <i>JAMA Cardiology</i> , 2023, 8, 177.	3.0	9
1180	Angina in 2022: Current Perspectives. <i>Journal of Clinical Medicine</i> , 2022, 11, 6891.	1.0	3
1181	Association between psoriasis and coronary artery calcification: A systematic review and meta-analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
1182	NLRP3-Inflammasome Inhibition with IZD334 Does Not Reduce Cardiac Damage in a Pig Model of Myocardial Infarction. <i>Biomedicines</i> , 2022, 10, 3056.	1.4	3
1183	Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR) recommendations for cardiovascular risk management?. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 457-459.	0.5	4
1184	Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 324-330.	0.5	21
1186	Rationale and design of COLchicine On-admission to Reduce inflammation in Acute Coronary Syndrome (COLOR-ACS) study. <i>Journal of Cardiovascular Medicine</i> , 2023, 24, 52-58.	0.6	3
1187	The Role of the Coagulation System in Peripheral Arterial Disease: Interactions with the Arterial Wall and Its Vascular Microenvironment and Implications for Rational Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14914.	1.8	5
1188	Targeting the reduction of inflammatory risk associated with cardiovascular disease by treating periodontitis either alone or in combination with a systemic anti-inflammatory agent: protocol for a pilot, parallel group, randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e063148.	0.8	2

#	ARTICLE	IF	CITATIONS
1189	Natural products against inflammation and atherosclerosis: Targeting on gut microbiota. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	7
1190	A Potential New Link Between Inflammation and Vascular Calcification. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	3
1191	Effects of Low-Dose Colchicine on Serum High-Sensitivity C-Reactive Protein Level in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus and Enhanced Inflammatory Response Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase 2, Dose-Finding Study. <i>Biomedicine Hub</i> , 2022, 7, 156-164.	0.4	1
1192	The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15937.	1.8	15
1193	<i>Edgeworthia gardneri</i> (Wall.) Meisn. extract protects against myocardial infarction by inhibiting NF- κ B-and MAPK-mediated endothelial inflammation. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
1194	Ulcerative colitis increases risk of hypertension in a UK biobank cohort study. <i>United European Gastroenterology Journal</i> , 2023, 11, 19-30.	1.6	5
1195	Phenotyping for percutaneous coronary intervention and long-term recurrent weighted outcomes. <i>International Journal of Cardiology</i> , 2022, , .	0.8	0
1196	Acute Coronary Syndrome: Unravelling the Biology to Identify New Therapies. <i>Cells</i> , 2022, 11, 4136.	1.8	1
1197	The IL-1 Family and Its Role in Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 17.	1.8	9
1198	Targeting cardiomyocyte ADAM10 ectodomain shedding promotes survival early after myocardial infarction. <i>Nature Communications</i> , 2022, 13, .	5.8	5
1199	Quo Vadis? Immunodynamics of Myeloid Cells after Myocardial Infarction. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15814.	1.8	2
1200	Drug repurposing for cardiovascular diseases: New targets and indications for probenecid. <i>British Journal of Pharmacology</i> , 2023, 180, 685-700.	2.7	5
1201	Clinical and Coronary Plaque Predictors of Atherosclerotic Nonresponse to Statin Therapy. <i>JACC: Cardiovascular Imaging</i> , 2023, 16, 495-504.	2.3	4
1202	Plant-Based Diets and Lipid, Lipoprotein, and Inflammatory Biomarkers of Cardiovascular Disease: A Review of Observational and Interventional Studies. <i>Nutrients</i> , 2022, 14, 5371.	1.7	8
1203	Coronary Flow Reserve, Inflammation, and Myocardial Strain. <i>JACC Basic To Translational Science</i> , 2023, 8, 141-151.	1.9	3
1204	Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial. <i>International Journal of Cardiology</i> , 2023, 372, 1-5.	0.8	11
1205	Bone and Joint Disorders. , 2023, , 1-40.		0
1206	Detection strategies for elevated lipoprotein(a): will implementation let the genie out of the bottle?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 0, Publish Ahead of Print, .	1.2	2

#	ARTICLE	IF	CITATIONS
1207	Translating atherosclerosis research from bench to bedside: navigating the barriers for effective preclinical drug discovery. <i>Clinical Science</i> , 2022, 136, 1731-1758.	1.8	4
1208	Repurposing of Chemotherapeutics to Combat COVID-19. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 2660-2694.	1.0	5
1209	Targeting inflammation in hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2023, 32, 111-117.	1.0	4
1210	Endothelial Dysfunction and Chronic Inflammation: The Cornerstones of Vascular Alterations in Age-Related Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15722.	1.8	12
1211	Colchicine Drug Interaction Errors and Misunderstandings: Recommendations for Improved Evidence-Based Management. <i>Drug Safety</i> , 2023, 46, 223-242.	1.4	9
1212	Monocyte to high-density lipoprotein ratio presents a linear association with atherosclerosis and nonlinear association with arteriosclerosis in elderly Chinese population: The Northern Shanghai Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	1.1	0
1213	Leukocyte Count Predicts Carotid Artery Stenosis in Men with Ischemic Stroke: Sub Study of the Preventive Antibiotics in Stroke Study (PASS). <i>Journal of Clinical Medicine</i> , 2022, 11, 7286.	1.0	0
1214	Phenotype-based screening rediscovered benzopyran-embedded microtubule inhibitors as anti-neuroinflammatory agents by modulating the tubulin- α 5 interaction. <i>Experimental and Molecular Medicine</i> , 2022, 54, 2200-2209.	3.2	1
1215	Inflammation and Heart Failure: Searching for the Enemy-“Reaching the Entelechy. <i>Journal of Cardiovascular Development and Disease</i> , 2023, 10, 19.	0.8	4
1216	Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases. <i>Pharmaceuticals</i> , 2023, 16, 78.	1.7	5
1217	Advances in immunotherapy modalities for atherosclerosis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
1218	Macrophages in cardiac remodelling after myocardial infarction. <i>Nature Reviews Cardiology</i> , 2023, 20, 373-385.	6.1	28
1219	Akutes Koronarsyndrom. <i>Springer Reference Medizin</i> , 2022, , 1-53.	0.0	0
1220	Immunomodulatory effects of colchicine on peripheral blood mononuclear cell subpopulations in human obesity: Data from a randomized controlled trial. <i>Obesity</i> , 2023, 31, 466-478.	1.5	4
1221	Clonal hematopoiesis and associated cardiovascular diseases. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	0
1222	Post-PCI Risk Assessment by Inflammation Activity According to Disease Acuity and Time from Procedure. <i>Thrombosis and Haemostasis</i> , 0, , .	1.8	1
1223	Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis. <i>Cardiology and Therapy</i> , 2023, 12, 171-181.	1.1	2
1224	Immune Profiling Reveals Decreases in Circulating Regulatory and Exhausted T _H 17 Cells in Human Hypertension. <i>JACC Basic To Translational Science</i> , 2023, 8, 319-336.	1.9	9

#	ARTICLE	IF	CITATIONS
1225	Association between dietary inflammatory index and atherosclerosis cardiovascular disease in U.S. adults. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	6
1226	Cardiovascular manifestations of monogenic periodic fever syndromes. <i>Clinical Rheumatology</i> , 2023, 42, 2717-2732.	1.0	2
1227	Natural Cell Patches: Melanin Nanoparticles for MR Imagingâ€Guided Antiatherosclerosis Therapy via Attenuating Macrophage Pyroptosis. <i>Advanced Functional Materials</i> , 2023, 33, .	7.8	3
1228	The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2023, 9, 311-317.	1.4	2
1229	Heartâ€Brain Team Approach of Acute Myocardial Infarction Complicating Acute Stroke: Characteristics of Guidelineâ€Recommended Coronary Revascularization and Antithrombotic Therapy and Cardiovascular and Bleeding Outcomes. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	2
1230	Impact of Metabolic Activity of Vertebra and Amygdala on Stroke Recurrence: A Prospective Cohort Study. <i>Circulation: Cardiovascular Imaging</i> , 2023, 16, .	1.3	5
1231	The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients. <i>Cardiovascular Therapeutics</i> , 2023, 2023, 1-9.	1.1	0
1232	Single-cell atlas reveals different immune environments between stable and vulnerable atherosclerotic plaques. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1233	Response to Athyros and Colleagues: Inflammation and LDL Reduction. <i>Current Vascular Pharmacology</i> , 2023, 21, 71-72.	0.8	0
1234	Canonical and non-canonical functions of NLRP3. <i>Journal of Advanced Research</i> , 2023, 53, 137-151.	4.4	4
1235	Worsening Thrombotic Complication of Atherosclerotic Plaques Due to Neutrophils Extracellular Traps: A Systematic Review. <i>Biomedicines</i> , 2023, 11, 113.	1.4	8
1237	Lo mejor del 2020: estudios que marcarÃ¡n nuestra prÃ¡ctica clÃ­nica. <i>Archivos Peruanos De CardiologÃ­a Y CirugÃ­a Cardiovascular</i> , 2021, 1, 200-205.	0.1	0
1238	Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
1239	Role of plaque inflammation in symptomatic carotid stenosis. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	2
1240	Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2483.	1.8	5
1241	Low-Dose Colchicine Attenuates Sepsis-Induced Liver Injury: A Novel Method for Alleviating Systemic Inflammation. <i>Inflammation</i> , 0, , .	1.7	0
1242	Plasma Lipoprotein Lipase Is Associated with Risk for Future Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy. <i>European Journal of Vascular and Endovascular Surgery</i> , 2023, , .	0.8	0
1243	Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2079.	1.8	7

#	ARTICLE	IF	CITATIONS
1244	Improving Cardiovascular Risk Assessment to Optimize Therapy. World Journal of Cardiovascular Diseases, 2023, 13, 7-20.	0.0	1
1245	Current Applications and New Perspectives in Optical Coherence Tomography (OCT) Coronary Atherosclerotic Plaque Assessment: From PCI Optimization to Pharmacological Treatment Guidance. Photonics, 2023, 10, 158.	0.9	0
1246	Detecting the Vulnerable Patient: Toward Preventive Imaging by Coronary Computed Tomography Angiography. Circulation: Cardiovascular Imaging, 0, , .	1.3	0
1247	Immunothrombosis: Molecular Aspects and New Therapeutic Perspectives. Journal of Clinical Medicine, 2023, 12, 1399.	1.0	5
1248	Integrated whole-genome gene expression analysis reveals an atlas of dynamic immune landscapes after myocardial infarction. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	1
1249	Prognostic role of <scp>CRP</scp> independent inflammatory patterns in patients undergoing primary percutaneous interventions. European Journal of Clinical Investigation, 2023, 53, .	1.7	1
1250	Fifteen-Year Nationwide Trend in Antiplatelet Treatment among Drug-Eluting Stent Recipients in Korea: Many Patients Receive Very Prolonged Dual-Antiplatelet Treatment, and Newer Drugs Are Replacing the Older Ones. Journal of Clinical Medicine, 2023, 12, 2675.	1.0	1
1251	Effect of colchicine and aspirin given together in patients with moderate COVID-19. Contemporary Clinical Trials Communications, 2023, 32, 101070.	0.5	1
1252	The heterogeneous cellular landscape of atherosclerosis: Implications for future research and therapies. A collaborative review from the EAS young fellows. Atherosclerosis, 2023, 372, 48-56.	0.4	3
1253	Rationale and design of the colchicine for the prevention of perioperative atrial fibrillation in patients undergoing major noncardiac thoracic surgery (COP-AF) trial. American Heart Journal, 2023, 259, 87-96.	1.2	1
1254	Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Expert Opinion on Pharmacotherapy, 2023, 24, 453-471.	0.9	5
1255	Targeting thromboinflammation in antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2023, 21, 744-757.	1.9	11
1256	Could colchicine reduce cardiovascular events in coronary artery disease without increasing all-cause mortality: Avoid optical illusions!. International Journal of Cardiology, 2023, 376, 125-126.	0.8	0
1257	Personalised Approach to Atherosclerotic Cardiovascular Disease: The Future is Here. EMJ Cardiology, 0, , 2-10.	0.0	0
1258	Advances in the Assessment of Coronary Artery Disease Activity with PET/CT and CTA. Tomography, 2023, 9, 328-341.	0.8	5
1259	Herz-Kreislauf-Risiko bei rheumatoider Arthritis: Medikamente reduzieren Entzündungen in Arterien. , 0, , .		0
1260	NDRG1: A New Regulator of Vascular Inflammation and Atherothrombosis. Circulation Research, 2023, 132, 320-322.	2.0	0
1261	Characterization of the effect of the GLUT-1 inhibitor BAY-876 on T cells and macrophages. European Journal of Pharmacology, 2023, 945, 175552.	1.7	4

#	ARTICLE	IF	CITATIONS
1262	Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence. <i>Journal of Clinical Medicine</i> , 2023, 12, 1302.	1.0	9
1263	The low-dose colchicine in patients after non-CABG cardiac surgery: a randomized controlled trial. <i>Critical Care</i> , 2023, 27, .	2.5	5
1264	Walnut inclusion in a palm oil-based atherogenic diet promotes traits predicting stable atheroma plaque in Apoe-deficient mice. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	1
1265	Actualit�s cardiologiques de la colchicine. , 2022, , 191-197.		0
1266	Chronic rheumatologic disorders and cardiovascular disease risk in women. <i>American Heart Journal Plus</i> , 2023, 27, 100267.	0.3	2
1267	Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 601-610.	0.8	7
1268	Higher Leukocyte Count Is Associated with Lower Presence of Carotid Lipid-Rich Necrotic Core: A Sub-Study in the Plaque at RISK (PARISK) Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 1370.	1.0	1
1269	Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches. <i>Drug Delivery and Translational Research</i> , 2023, 13, 1983-2014.	3.0	3
1270	Meta-analysis of the effect of colchicine on C-reactive protein in patients with acute and chronic coronary syndromes. <i>Coronary Artery Disease</i> , 2023, 34, 210-215.	0.3	3
1271	ANGPTL4 stabilizes atherosclerotic plaques and modulates the phenotypic transition of vascular smooth muscle cells through KLF4 downregulation. <i>Experimental and Molecular Medicine</i> , 2023, 55, 426-442.	3.2	10
1272	Association of endometriosis with cardiovascular disease: Genetic aspects (Review). <i>International Journal of Molecular Medicine</i> , 2023, 51, .	1.8	8
1273	Frontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease: A bibliometric analysis of 1990�2022. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	4
1274	Innate immune memory in cardiometabolic disease. <i>Cardiovascular Research</i> , 2024, 119, 2774-2786.	1.8	12
1275	The Effect of Colchicine on Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Cureus</i> , 2023, , .	0.2	1
1276	Mechanism of oxidized phospholipid-related inflammatory response in vascular ageing. <i>Ageing Research Reviews</i> , 2023, 86, 101888.	5.0	2
1277	Multiancestry Genome-Wide Association Study of Aortic Stenosis Identifies Multiple Novel Loci in the Million Veteran Program. <i>Circulation</i> , 2023, 147, 942-955.	1.6	21
1278	Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein. <i>European Heart Journal</i> , 2023, 44, 1449-1460.	1.0	17
1279	Impact of Reperfusion on Temporal Immune Cell Dynamics After Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	4

#	ARTICLE	IF	CITATIONS
1280	Trained immunity in monocyte/macrophage: Novel mechanism of phytochemicals in the treatment of atherosclerotic cardiovascular disease. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1281	Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. <i>BMJ Open</i> , 2023, 13, e067910.	0.8	7
1282	Cost-Effectiveness of Colchicine for Recurrent Cardiovascular Events. <i>CJC Open</i> , 2023, 5, 348-356.	0.7	1
1283	A spotlight on Fibroblast-activated protein inhibitor (FAPi) cardiovascular imaging. <i>Clinical and Translational Imaging</i> , 2023, 11, 229-233.	1.1	4
1284	Peri-coronary adipose tissue is a predictor of stent failure in patients undergoing percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2023, , .	0.3	0
1285	Colchicine exerts anti-atherosclerotic and plaque-stabilizing effects targeting foam cell formation. <i>FASEB Journal</i> , 2023, 37, .	0.2	9
1286	Risk of coronary artery disease in patients with gout on treatment with Colchicine: A systematic review and meta-analysis. <i>IJC Heart and Vasculature</i> , 2023, 45, 101191.	0.6	0
1287	Inflammation contributes to cardiovascular risk in patients receiving statin therapy. <i>Lancet, The</i> , 2023, 401, 1245-1247.	6.3	4
1288	Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. <i>Lancet, The</i> , 2023, 401, 1293-1301.	6.3	106
1289	Complexity of Inflammation in the Trajectory of Vascular Disease: Interleukin 6 and Beyond. <i>Annals of Vascular Diseases</i> , 2023, 16, 8-16.	0.2	2
1290	Intracoronary Imaging of Coronary Atherosclerotic Plaque: From Assessment of Pathophysiological Mechanisms to Therapeutic Implication. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5155.	1.8	5
1291	Validation and Comparison of the Prognosis Predicting Ability of Inflammation-Based Scores Following Endovascular Treatment for Peripheral Artery Disease. <i>Angiology</i> , 0, , 000331972311613.	0.8	1
1293	Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets. <i>Journal of Clinical Medicine</i> , 2023, 12, 2161.	1.0	6
1294	Management of Dysregulated Immune Response in the Critically Ill: Heart and Circulation. <i>Lessons From the ICU</i> , 2023, , 171-188.	0.1	0
1295	OCT Emerging Technologies: Coronary Micro-optical Coherence Tomography. <i>Interventional Cardiology Clinics</i> , 2023, 12, 237-244.	0.2	0
1296	Intravascular Ultrasound and Optical Coherent Tomography Combined Catheter. <i>Interventional Cardiology Clinics</i> , 2023, 12, 187-201.	0.2	0
1297	The Protective Role of TREM2 in the Heterogenous Population of Macrophages during Post-Myocardial Infarction Inflammation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5556.	1.8	2
1298	A comparative gene expression matrix in Apoe-deficient mice identifies unique and atherosclerotic disease stage-specific gene regulation patterns in monocytes and macrophages. <i>Atherosclerosis</i> , 2023, 371, 1-13.	0.4	1

#	ARTICLE	IF	CITATIONS
1299	Colchicine Use and Major Adverse Cardiovascular Events in Male Patients with Gout and Established Coronary Artery Disease: A Veterans Affairs Nested Retrospective Cohort Study. , 2023, 1, 11-24.		1
1300	Clinical implications of inflammation in atheroma formation and novel therapies in cardiovascular diseases. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	1
1301	Role of plaque imaging for identification of vulnerable patients beyond the stage of myocardial ischemia. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1
1303	Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5714.	1.8	0
1304	History of peripheral artery disease and cardiovascular risk of real-world patients with acute coronary syndrome: Role of inflammation and comorbidities. <i>International Journal of Cardiology</i> , 2023, 382, 76-82.	0.8	9
1305	A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5983.	1.8	2
1306	Improving diagnostic assessments in the ever-changing landscape of atherosclerosis. <i>Journal of Cardiovascular Medicine</i> , 2023, 24, 221-229.	0.6	1
1307	Immunity and inflammation in cardiovascular disorders. <i>BMC Cardiovascular Disorders</i> , 2023, 23, .	0.7	5
1308	Impact of Impaired Cholesterol Homeostasis on Neutrophils in Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2023, 43, 618-627.	1.1	8
1309	Medical Therapy to Prevent or Slow Progression of Aortic Stenosis: Current Evidence and Future Directions. <i>Cardiology in Review</i> , 0, Publish Ahead of Print, .	0.6	1
1310	Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease. <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 291-299.	1.9	3
1311	ZBP1 Protects Against mtDNA-Induced Myocardial Inflammation in Failing Hearts. <i>Circulation Research</i> , 2023, 132, 1110-1126.	2.0	9
1312	Adventitial adaptive immune cells are associated with ascending aortic dilatation in patients with a bicuspid aortic valve. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	0
1313	Lipoprotein (a), Inflammation, and Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2023, 12, 2529.	1.0	7
1314	Neutrophils in Health and Disease: From Receptor Sensing to Inflammasome Activation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6340.	1.8	1
1315	Thymidine Phosphorylase Deficiency or Inhibition Preserves Cardiac Function in Mice With Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	2
1317	Hirudin ameliorates myocardial ischemiaâ€“reperfusion injury in a rat model of hemorrhagic shock and resuscitation: roles of NLRP3-signaling pathway. <i>Molecular and Cellular Biochemistry</i> , 2024, 479, 63-72.	1.4	0
1318	Not Only Excruciating Pain â€“Might a Gout Flare Episode Lead to Pulmonary Embolism?. <i>Arthritis and Rheumatology</i> , 0, , .	2.9	0

#	ARTICLE	IF	CITATIONS
1319	Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials. <i>Atherosclerosis</i> , 2023, 373, 1-9.	0.4	5
1320	Colchicine may be considered for the secondary prevention of cardiovascular disease. <i>Drugs and Therapy Perspectives</i> , 0, , .	0.3	0
1321	Evolving Diagnostic and Management Advances in Coronary Heart Disease. <i>Life</i> , 2023, 13, 951.	1.1	3
1322	Immunologic Mechanisms of Atherosclerosis and Myocarditis. , 2023, , 883-897.		0
1323	Efficacy and safety of different dosing regimens of colchicine in patients with coronary artery disease: a network meta-analysis of 15 randomized controlled trials. <i>Journal of Cardiovascular Pharmacology</i> , 2023, Publish Ahead of Print, .	0.8	0
1324	Inflammatory Markers and Risk of Cardiovascular Events in Ischemic Stroke. <i>Stroke</i> , 0, , .	1.0	0
1325	Chronic venous disease and cardiovascular disease. <i>Medicína Pro Praxi</i> , 2023, 20, 17-24.	0.0	1
1326	High absolute neutrophil count with type 2 diabetes is associated with adverse outcome in patients with coronary artery disease: A large-scale cohort study. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	2
1327	Biomarker-associated Monocyte Inflammatory Signaling in Myocardial Infarction. <i>International Journal of Cardiovascular Sciences</i> , 2023, 36, .	0.0	0
1328	Revascularization and Medical Therapy for Chronic Coronary Syndromes: Lessons Learnt from Recent Trials, a Literature Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 2833.	1.0	5
1330	Soluble interleukin-2 receptor combined with interleukin-8 is a powerful predictor of future adverse cardiovascular events in patients with acute myocardial infarction. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	2
1331	New Insights into Pathophysiology and New Risk Factors for ACS. <i>Journal of Clinical Medicine</i> , 2023, 12, 2883.	1.0	3
1332	Cholesterol Crystals as the Main Trigger of Interleukin-6 Production through Innate Inflammatory Response in Human Spontaneously Ruptured Aortic Plaques. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 1715-1726.	0.9	5
1333	Dihydrotestosterone, and Not Testosterone, Enhances the LPS-Induced Inflammatory Cytokine Gene Expression in Human Adipocytes. <i>Biomedicines</i> , 2023, 11, 1194.	1.4	1
1334	Presence of tophi and carotid plaque were risk factors of MACE in subclinical atherosclerosis patients with gout: a longitudinal cohort study. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1335	Therapeutic Innovations for Heart Failure. <i>Cardiac and Vascular Biology</i> , 2023, , 337-353.	0.2	0
1336	C-reactive protein and cardiovascular diseases: a synthesis of studies based on different designs. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 1593-1596.	0.8	4
1337	Understanding the molecular mechanisms of statin pleiotropic effects. <i>Archives of Toxicology</i> , 2023, 97, 1529-1545.	1.9	9

#	ARTICLE	IF	CITATIONS
1341	Hallmarks of cardiovascular ageing. <i>Nature Reviews Cardiology</i> , 2023, 20, 754-777.	6.1	28
1344	The Effects and Treatment of Inflammation on Diabetes Mellitus and Cardiovascular Disease. <i>Contemporary Cardiology</i> , 2023, , 307-329.	0.0	0
1352	Anti-inflammatory Therapy for Cardiovascular Disease. , 2024, , 224-235.e1.		0
1353	Treatment Guidelines Overview. , 2024, , 113-121.e2.		0
1358	Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. <i>Nature Reviews Rheumatology</i> , 2023, 19, 417-428.	3.5	15
1367	Editorial: The individualization of antiplatelet therapy in coronary artery disease: escalation or de-escalations. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	0
1379	Endothelial Dysfunction in Type 2 Diabetes with an Update on New Interventions. <i>Contemporary Diabetes</i> , 2023, , 357-406.	0.0	0
1397	High-Sensitivity C-Reactive Protein. , 2024, , 69-78.e2.		0
1435	Scientific Landscape of Oxidative Stress in Stroke: From a Bibliometric Analysis to an in-Depth Review. <i>Neurochemical Research</i> , 2023, 48, 3327-3348.	1.6	3
1436	A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease. <i>Clinical Research in Cardiology</i> , 0, , .	1.5	0
1464	Immunomodulation and immunopharmacology in heart failure. <i>Nature Reviews Cardiology</i> , 2024, 21, 119-149.	6.1	1
1475	Effects of lifestyle factors on leukocytes in cardiovascular health and disease. <i>Nature Reviews Cardiology</i> , 2024, 21, 157-169.	6.1	0
1499	Targeted imaging: the key for direct visualization of myocardial inflammation in patients?. <i>Journal of Nuclear Cardiology</i> , 2023, 30, 2556-2558.	1.4	0
1505	Inflammation and Vascular Pathologies. <i>Contemporary Endocrinology</i> , 2023, , 147-163.	0.3	0
1533	Potential Benefits of Bioactive Functional Components of Citrus Fruits for Health Promotion and Disease Prevention. , 2023, , 451-499.		0
1536	The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. <i>Nature Reviews Cardiology</i> , 0, , .	6.1	6
1551	Omega-3 Fatty Acids Influence Membrane Cholesterol Distribution and Crystal Formation in Models of Atherosclerosis. <i>Contemporary Cardiology</i> , 2023, , 297-318.	0.0	0
1555	Cardio-Rheumatology and Women's Hearts. , 2023, , 219-231.		0

#	ARTICLE	IF	CITATIONS
1581	Agents That Affect Cholesterol Crystallization and Modify the Risk of Crystal Induced Traumatic and Inflammatory Injury. Contemporary Cardiology, 2023, , 467-489.	0.0	1
1582	Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis: Lessons for Cholesterol from the Land of Gout. Contemporary Cardiology, 2023, , 321-349.	0.0	0
1583	Role of CCs and Their Lipoprotein Precursors in NLRP3 and IL-1 β Activation. Contemporary Cardiology, 2023, , 257-274.	0.0	0
1585	Gut Microbiome in Dyslipidemia and Atherosclerosis. Endocrinology, 2023, , 1-29.	0.1	0
1590	Elevations in Creatine Kinase are Not Related to the Choice or Dose of Statins in Patients Taking Colchicine 0.5 mg Daily: Insights from the LoDoCo2 Trial. Clinical Drug Investigation, 2023, 43, 575-577.	1.1	0
1594	Atherosclerosis antigens as targets for immunotherapy. , 2023, 2, 1129-1147.		0
1604	Geschlechtsspezifische Aspekte bei Herz-Kreislauf-Erkrankungen. , 2023, , 91-137.		0
1608	Akutes Koronarsyndrom. Springer Reference Medizin, 2023, , 23-74.	0.0	0
1611	Atherosclerotic plaque stabilization and regression: a review of clinical evidence. Nature Reviews Cardiology, 0, , .	6.1	1
1614	Macrophage profiling in atherosclerosis: understanding the unstable plaque. Basic Research in Cardiology, 2024, 119, 35-56.	2.5	0
1639	Circular RNAs: Regulators of endothelial cell dysfunction in atherosclerosis. Journal of Molecular Medicine, 2024, 102, 313-335.	1.7	0
1648	Gut Microbiome in Dyslipidemia and Atherosclerosis. Endocrinology, 2024, , 231-258.	0.1	0
1663	Bone and Joint Disorders. , 2024, , 721-760.		0